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ABSTRACT 
 
 Protein modification by conjugation of SUMO molecules to target proteins  
is an essential process for both genomic stability and cell viability.  In vertebrates, 
the SUMOylation process involves three SUMO paralogues, SUMO 1, 2, and 3. 
During cell division, certain chromosome-associated protein are modified by 
SUMO2/3;  however, the regulatory mechanisms that monitor and control the 
SUMOylation process are poorly defined.   
 Previous studies have revealed that DNA Topoisomerase IIα (TopoIIα) is 
a mitotic target of SUMO2/3, and that defects in TopoIIα SUMOylation are linked 
to chromosomal missegregation, suggesting a relationship between TopoIIα 
SUMOylation and the regulation of mitotic progression. Using an in vitro 
SUMOylation and decatenation assay with recombinant TopoIIα protein, we 
demonstrated that SUMO conjugation inhibits the intrinsic activity of TopoIIα.  By 
mass spectrometry and biochemical analysis, we identified Lys 660 of TopoIIα as 
a SUMOylation site in both Xenopus egg extracts (XEE) and in vitro assays.  Lys 
660 is located within the catalytic domain of TopoIIα and elimination of Lys 660 
SUMOylation by mutation abolished the SUMOylation-mediated inhibition of 
TopoIIα activity that is normally observed in wildtype (WT), suggesting that Lys 
660 SUMOylation is responsible for regulating TopoIIα activity.  In addition, 
biochemical analysis has shown that SUMO conjugation of Lys 660 requires the 
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presence of DNA, suggesting that catalytically active TopoIIα is a target of 
SUMO conjugation during mitosis.  
  Subsequent investigations of mitotic SUMOylation, lead to the isolation of 
SUMOylated forms of another protein from mitotic chromosomes.  Using mass 
spectrometry, we identified this protein, poly (ADP-ribose) polymerase 1 
(PARP1) as another SUMO2/3 target during mitosis.  Similar to the conjugation 
pattern seen with TopoIIα, SUMO conjugation of PARP1 first appears during 
prometaphase, shows the strongest intensity during metaphase, and disappears 
with the onset of anaphase.  Interruption of SUMOylation increased PARP1-
dependant PARylation, implicating SUMO2/3 conjugation in the regulation of 
mitotic PARylation.  
           We also investigated the role of PIASy, a SUMO E3 enzyme of the 
SIZ/PIAS family that is essential for the completion of SUMO2/3 modification 
during mitosis.  Analysis of PIAS family proteins has shown that only PIASy is 
able to bind to chromosomes during mitosis.  Domain analysis has suggested 
that the N-terminus of PIASy is responsible for chromosome binding.  In our 
studies, we analyzed the functional importance of the N-terminus of PIASy using 
recombinant PIAS N-terminal truncations.  We demonstrated that the most N-
terminal region of PIASy is not involved in either substrate binding or in SUMO 
modification; however, it is required for governing chromosome interaction.  
Furthermore, an ~130 amino acid polypeptide located at the N-terminus of PIASy 
was capable of accumulating at the centromere, the site where most mitotic 
SUMO2/3 conjugation takes place.  Mass spectrometry following pull-down 
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assays have shown that Rod/Zw10, a critical component of spindle checkpoints,  
specifically interacts with the N-terminus of PIASy, but not with other PIAS family 
members.  We demonstrated that elimination of Rod proteins by 
immunodepletion in XEE causes mislocalization of PIASy on mitotic 
chromosomes followed by abnormal SUMOylation. 
           In summary, we have investigated how SUMOylation is regulated in a 
spatial and temporal manner by the SUMO E3 ligase, PIASy.  We have also 
analyzed the function of SUMO conjugation during mitosis using two SUMO 
target proteins, TopoIIα and PARP1.  Our in vitro reconstitution assay has 
enabled us to closely examine the nature of mitotic SUMOylation and has 
demonstrated potential roles for SUMOylation during mitosis. Together, these 
results contribute to the understanding of mitotic SUMO conjugations and raise 
specific questions for future studies. 
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CHAPTER 1 
INTRODUCTION: SUMOylation, MITOSIS, The ROLES of 
SUMOylation, and SUMO E3 LIGASE  
 
Part Ι . SUMOylation 
 SUMOylation is a post-translational process in which a SUMO (small 
ubiquitin-related modifier) protein (~100 amino acids) is conjugated to targets (1) 
(Figure 1.1). SUMOylation is highly conserved in eukaryotes (1).  Lower 
eukaryotes, including yeast, worm, and fruit fly, utilize a single SUMO (SUMO1) 
(2,3).  Higher eukaryotes have developed more sophisticated mechanisms, 
alternatively utilizing different SUMO paralogues depending on environmental 
states within the cell (2,4).  In vertebrates, there are three SUMO parologues:  
SUMO1, 2, and 3 (Table 1.1).  
 15 
 
Figure 1. 1 
Structural comparison of SUMO1 and Ubiquitin.  A and B. SUMO1 shows high structural similarity 
to ubiquitin even though SUMO1 and ubiquitin share only ~20% sequence identity  (Adapted from 
Melchior, 2000 (1)). 
 
 SUMO1 is ~50% identical in sequence to both SUMO2 and SUMO3 while 
SUMO2 and SUMO3 are ~95% identical in sequence (Table 1.1).  Because of 
the inability to distinguish SUMO2 and SUMO3 by antibodies, SUMO2 and 
SUMO3 are collectively grouped as SUMO2/3. 
 16 
 
Table 1. 1 
Sequence comparison of SUMO paralogues. A single SUMO (Smt3p) in S. cerevisiae shows 
roughly 50% similarity to each SUMO in vertebrates. Vertebrate SUMO1 displays ~50% identity 
to both SUMO2 and SUMO3, while SUMO2 and SUMO3 are highly similar in sequence and 
cannot be distinguished by antibodies in vivo.  
 
 SUMO is covalently attached to its target substrates through an enzymatic 
conjugation cascade similar to the biochemical process of ubiquitination (5).  
However, the SUMOylation process utilizes unique components:  SUMO E1 
activating enzyme, E2 conjugating enzyme Ubc9, and several E3 ligating 
enzymes (Figure 1.2) (5).  SUMO E1 is composed of Aos1 and Uba2 enzymes to 
form an Aos1/Uba2 heterodimer, and initiates SUMO attachment by activating 
the formation of a thioester bond between the mature form of SUMO and E1 
Uba2.  Subsequently, SUMO E2, Ubc9, takes the activated SUMO and transfers 
it to the ε-amino group of the substrate with the aid of an E3 ligase.  The region 
of the target substrate that is directly bound by Ubc9 is called the “SUMOylation 
concensus sequence” and is composed of the amino acid sequence ΨKXE, 
where Ψ is a hydrophobic branched amino acid, K is the lysine residue that will 
be SUMOylated, X is any amino acid, and E is glutamic acid (1,6,7).   
 17 
 Although there are reports that Ubc9 recognizes its target proteins without 
the aid of SUMO E3, accumulating data suggests that E3 ligases are necessary 
for recognition of targets in vivo (7-10).  Evidence of this includes the yeast strain 
(ΔSiz)  that is lacking a major E3 ligase and has lost most of its capacity for 
SUMOylation (11,12).  Also, immunodepletion of the E3 ligase PIASy, completely 
eliminates SUMOylation during mitosis in Xenopus egg extracts (XEE) (8).  
Lastly, SUMOylation is reversed by SUMO specific proteases (Fig 1.2) (13,14).  
There are six SUMO specific proteases in vertebrates called SENP (Sentrin 
specific proteases) 1, 2, 3, 5, 6, and 7 (14).  Accumulating reports have shown 
that distinct subcellular localization of these SUMO proteases allows the 
deconjugation of specific SUMOylated target proteins (13).  
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Figure 1. 2 
The SUMO conjugation pathway.  Using unique E1, E2, and E3 enzymes, SUMO is conjugated to 
various targets in vivo and in vitro, in order to modify target function.  SUMO conjugation is highly 
dynamic, and the process is reversible by the action of SUMO proteases that cleave SUMO from 
the target proteins. Su stands for SUMO paralogues, E1 for E1 activating enzyme, E2 for 
conjugating enzyme, E3 for ligase protein. (Adapted from Hay, 2005 (2)). 
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Part ΙΙ . Mitosis and chromosome segregation  
 The eukaryotic cell undergoes two biochemically discrete phases in order 
to proliferate:  interphase and mitosis.  Interphase is the period in which the cell 
prepares for division of its genomic material.  During this phase, the cell 
expresses proteins required for chromsome condensation and cell division, 
replicates its DNA, and subsequently inspects for DNA damage before  entry into 
mitosis.   
 Mitosis is a highly transient and dynamic stage that is subdivided into five 
phases:  prophase, prometaphase, metaphase, anaphase, and telophase.  
During prophase, chromatin starts to condense and two centrosomes are 
positioned on opposite sides of the nucleus.  The cell also begins to lose its 
nuclear envelope during prophase.  In prometaphase, growing spindles search 
for chromosomes and arrange these chromosomes near the metaphase plate.  
At metaphase, all the chromosomes are aligned at the metaphase plate, located 
between the two spindle poles.  After both the spindle assembly checkpoint and 
the tension checkpoint are completed, sister chromatids move towards opposite 
spindle poles, and are physically divided into two sets of chromosomes during 
anaphase.   In telophase, the nuclear envelope reforms, followed by completion 
of cytokinesis (Figure 1.3) (15).  
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Figure 1.3 
Schematic diagram of the cell division cycle. Cells go through a series of events, each of which is 
characterized by specific features.  Mitosis is the process whereby the cell attempts to divide into 
two daughter cells, each of which inherits the same quantity of genomic material. Mitosis is 
comprised of five phases: prophase, prometaphase, metaphase, anaphase, and telophase.  
(Adapted from Salaün et al., 2008 (15)). 
 
 In order to pass on genomic material with high fidelity, there is a 
specialized region of the cell called the kinetochore that is dedicated to 
chromosome segregation (16).  The kinetochore is composed of multiple protein 
complexes built on the centromere (Figure 1.4) (16). All of the kinetochore 
proteins identified to date are required for either K-fiber formation (microtubule-
kinetochore interaction), mitotic checkpoints, or chromosome segregation (16-
19).   
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Figure 1. 4 
Schematic of a kinetochore on the chromosome.  The kinetochore is composed of three distinct 
structures:  the inner kinetochore, outer kinetochore, and fibrous corona. (Adapted from 
Cheezeman and Desai, 2008 (20) ).   
 
Rough deal and Zeste white 10 
Rod (Rough deal) and Zw10 (Zeste white 10) are outer kinetochore 
proteins (21).  Together with Zwilch protein, they form the RZZ complex (21).  
Rod and Zw10 are responsible for the recruitment of the mitotic checkpoint 
proteins, Mad1 and Mad2, which sequester Cdc20 (21,22).  Cdc20 is an activator 
of the anaphase promoting complex (APC/C) that is involved in the ubiquitination 
and proteasome-associated degradation of Securin and CyclinB (23,24).  
Therefore, Rod and Zw10 are required for the activation of mitotic checkpoint, 
and mutations in Rod and Zw10 cause premature sister chromatid segregation in 
the cell (25,26). 
 
DNA topoisomerase IIα  and poly(ADP-ribose) polymerase I 
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 DNA topoisomerase IIα (TopoIIα), is a crucial enzyme which, together with 
the kinetochore proteins, is required for proper chromosome segregation during 
mitosis (27,28).  TopoIIα supports the rod-shaped chromosome structure, and 
therefore is known as a scaffold protein (Figure 1.5) (29).  Numerous studies 
have implicated the catalytic activity of TopoIIα in chromosome condensation and 
segregation (27,30,31).  
 
Figure 1. 5 
Micrographic images of chromosome scaffold in metaphase. A. A metaphase chromosome 
consists of ~1/3 DNA, ~1/3 histone proteins, and ~1/3 non-histone proteins.  After harsh 
extraction such as treatment with high salt concentrations, non-histone proteins remain on the 
metaphase chromosome and maintain the shape of the chromosome. TopoIIα and SMC (Struc-
tural maintenance of chromosomes) family proteins provide the skeletal framework for the sister 
chromatids.  The inset shows an intact chromosome before harsh extraction. B. Light microscopic 
image of a single meiotic chromosome from an oocyte of Triburus viridescens. (Adapted from 
Bloom and Joglekar, 2010 (29)). 
 
 
 TopoIIα resolves DNA tangles by cleaving one DNA duplex, passing a 
second duplex through the cleaved first duplex, and religating the break, in an 
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ATP-dependent manner (Figure 1.6) (32).  The catalytic function of TopoIIα is 
tightly regulated although the mechanism for regulation has not been identified.   
TopoIIα activity is not observed in the fractions located on the chromosome 
arms;  it is only observed at the centromeric region of chromosomes during 
mitosis (33). The molecular mechanism and role of TopoIIα at the centromere 
during  mitosis are poorly understood. 
 
Figure 1.6 
Schematic diagram of the catalytic reactions of DNA Topoisomerase IIα.  The DNA gate segment 
is labeled G-segment;  transported DNA segment as T-segment.  TopoIIα binds the G-segment 
and changes its structure (1 and 2).  ATP is placed in the ATPase domain (in yellow) followed by 
binding of the T-segment (3).  Further conformational changes in TopoIIα allow the cleavage of 
the G-segment and transport of the T-segment (3 and 4).  The G-segment is resealed and the T-
segment is released as a final step (5).  (Adapted from Berger et al., 1996 (32)) 
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 Poly(ADP-ribose) polymerase I (PARP1) is a nuclear enzyme activated by 
DNA strand breaks (34).  Once activated, PARP1 attaches ADP-ribose moieties 
onto certain glutamate and lysine residues of target proteins (35). The process of 
PARP1-mediated polymerization using ADP-ribose onto target proteins is called 
PARylation.  Studies of PARP1 have implicated PARP1 in DNA damage repair 
systems (35,36).  It is likely that the presence of large, negatively charged ADP-
ribose polymers on substrate targets recruits proteins involved in DNA damage 
repair, such as XRCC1 (37).  XRCC1 is an adaptor protein that activates the 
DNA base excision repair machinery (37).  In addition, it was recently shown that 
PARP1-mediated PARylation regulates the activity of Aurora B kinase, which is 
responsible for the initiation of chromosome condensation, as well as 
segregation, at the onset of anaphase (38).  However, the detailed mechanism of 
this regulation remains poorly understood.     
 
Part III.  The functions of SUMOylation 
 SUMOylation is an essential biological event that is implicated in diverse 
cellular processes.  SUMO modifications have been shown to affect the 
transcription, localization, interaction, and regulation of activity of a variety of 
proteins, including those involved in chromosome morphology, and cell cycle 
progression (39-42).  
 SUMO modifications in vivo are either constitutive or cell cycle-specific.  
SUMO1 conjugations tend to be more stable than SUMO2/3 conjugations, and 
SUMO1 targets are immediately conjugated to SUMO1 once the targets are 
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expressed (43).  An example of this is the SUMOylation of RanGTPase activating 
protein 1 (RanGAP1).  RanGAP1 is constituitively conjugated to SUMO1, and the 
conjugated form of RanGAP1 is then able to interact with the nuclear pore 
complex (NPC) (43).  The localization of RanGAP1 on the cytoplasmic side of the 
NPC is known to be involved in regulation of nuclear cytoplasmic-trafficking (44).  
 Cell cycle-specific SUMOylation can be further divided into interphase- and 
mitosis-specific modifications. Accumulating reports have shown that, during 
interphase, several transcription factors are targeted for SUMO conjugation, 
resulting in repression of transcription (42).  An example of this involves AR- and 
Smad4-mediated transcription (45,46).  Daxx, a transcription cofactor, binds to 
the SUMOylated forms of AR and Smad4, and this interaction recruits histone 
deacetylase (HDAC) which represses AR- and Smad4-mediated transcription 
(26,45-48).  It has been demonstrated that mutagenized substrates (AR or 
Smad4) that have been rendered non-SUMOylatable are no longer inhibited by 
Daxx (47,48).   
The importance of mitosis-specific SUMOylation is evidenced by the 
mitotic defects manifested in SUMOylation-deficient organisms (41).  The SUMO 
knockout strain (Δsmt3) in budding yeast exhibits early mitotic arrest,  and the 
SUMO-deficient fission yeast strain (Δpmt3) exhibits aberrant chromosome 
structure and missegregation (49,50).  Mice lacking Ubc9 are embryonic lethal 
and exhibit severe mitotic defects (40).  
 Recently, proteomic screening in yeast has found over 300 potential 
targets for SUMOylation, the majority of which are centromere-resident proteins 
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(Figure 1.7) (51).  Examples of these include condensin- and cohesin-complex 
proteins, such as SMC (Structural maintenance of chromosomes) 1, 3, and 4 
(Figure 1.7) (51).  Pds5 is an inner-centromeric protein that mediates cohesin 
interaction with chromosomes in a SUMOylation-dependant manner (52).  As 
described in CHAPTER 3, TopoIIα activity is also regulated in a SUMO2/3 
modification-dependent manner.  A detailed mechanism for SUMOylation-
mediated regulation of mitotic progression has been poorly resolved owing to the 
complexity of mitosis. However, the evidence suggests that successful 
chromosome segregation and proper mitotic progression are dependent on a 
myriad of complex events involving SUMOylation (41).   
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Figure 1. 7 
The distribution of SUMO targets on mitotic chromosomes. A. Biological processes of SUMO-
modified proteins. B. The approximate localization of selected SUMOylation substrates are 
schematically displayed. Only target proteins verified by proteomic analysis are represented in 
this figure. Black indicates vertebrate proteins, and red indicates homologues in yeast.  ICR:  
inner centromere region. (Adapted from Denison et al., 2005 and M. Dasso, 2008 (41,51)). 
 
Part IV.  PIASy, a SUMO E3 ligase of the SIZ/PIAS family 
 28 
 There are two types of SUMO E3 ligases:  RING-domain dependent 
ligases, (the SIZ/PIAS family), and RING-domain independent ligases, (Pc2 and 
RanBP2, (also known as Nup358) enzymes) (11,53,54).  RanBP2 and Pc2 are 
specialized enzymes that have been identified in vertebrates and whose 
counterparts have not yet been found in yeast (54).  The structure of these 
enzymes is not the typical HECT- or RING-type ligase structure (55).   
 The RING-domain dependent E3 ligases are evolutionarily conserved 
from yeast to vertebrate (SIZ in yeast and PIAS in vertebrate) (56).  The 
vertebrate PIAS (protein inhibitor of activated STAT) family consists of PIAS1, 
PIAS3, PIASxα, PIASxβ, and PIASy (Figure 1.8) (56,57).  Initially discovered dur-
ing the process of identifying proteins that inhibit transcription of STAT proteins, 
several PIAS members are also well-known transcription repressors (57).  As 
shown in Figure 1.8, the PIAS family of E3 ligases share several motifs in 
common:  SAP (scaffold attachment factor A/B/acinus/PIAS), PINIT, SP-RING 
(SIZ/PIAS RING), and SIM (SUMO interacting motif) (57).  The SAP domain 
binds AT-rich regions of DNA (58).  PINIT is a conserved amino acid sequence 
involved in substrate interaction and localization (59).  SP-RING is a RING-like 
catalytic domain that interacts with the SUMO E2 conjugating enzyme, Ubc9 (8).  
The SIM region interacts with SUMO paralogues (60).  Domain analyses have 
indicated that all domains of PIAS are necessary for proper SUMO conjugation in 
vivo (8).  
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Figure 1. 8 
The primary structure of the PIAS family of SUMO E3 ligases.  The vertebrate PIAS family 
consists of PIAS1, 3, Xα, Xβ, and PIASy.  PIAS proteins contain a SAP domain at the N terminus, 
followed by PINIT, SP-RING, SIM, and finally S/DE domains at the C-terminus.  Domain analyses 
have identified functions for each domain in PIAS proteins, as described in the text.  
  
 Although PIAS family members display extensive sequence similarity with 
one another, the PIAS proteins have distinctive binding partners (57).  The SAP 
domains of PIAS proteins share more than 95% sequence identity among family 
members, however, several investigations have demonstrated that the SAP 
domain is actively involved in binding to unique transcription factors and 
regulators:  PIAS1 binds to p73, PIAS3 binds to p300/CBP, and PIAS4 binds to 
p53;  all of these interactions involve the SAP domain (57,61,62).  The 
mechanism of specific partner recognition in PIAS family members in vivo 
remains to be elucidated.  
 
Part V. Xenopus egg extract (XEE) cell free system 
Xenopus egg extract (XEE) is a powerful system to study cell cycle 
specific features (27,63). This is because chromosomes are arrested at 
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metaphase due to a cytostatic factor (CSF) that prevents anaphase entry (Fig. 
1.9).  By addition of calcium cloride solution, the metaphase-arrested extract is 
induced to interphase.  SUMO modification of certain target proteins such as 
TopoIIα and PARP1 occurs in a mitosis-specific manner (8,10). Therefore, by 
using XEE cell free system, we can examine mitotic SUMOylation while 
constitutive or interphase-specific SUMO modifications are not affected. 
 
Figure 1.9 
Preparation of Xenopus egg extracts (XEE).  Eggs are collected from Xenopus laevis which were 
induced using pregnant mare's serum gonadotropin and human chorionic gonadotropin. Col-
lected eggs are dejellyed and subjected to centrifugation in order to obtain the crude soluble frac-
tion. This fraction contains the cytostatic factor that allows chromosomes at metaphase. 
 
Part V. Summary 
 Genetic analysis has shown that cell cycle-specific SUMO conjugation is a 
vital process in the cell, demonstrated by the numerous errors in mitotic 
progression manifested in SUMOylation-deficient organisms (41).  The aim of 
this study was to generate a detailed description of the mechanism of 
SUMOylation during mitosis using both in vitro reconstitution assays and in vivo 
XEE cell-free systems.  We demonstrated that PIASy, a SUMO E3 ligase, 
functions through  N-terminal interaction with the centromeric region of 
chromosomes (Chapter 4).  We also determined that the Rod/Zw10 complex is 
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necessary for the proper localization of PIASy and for SUMO modification of 
centromeric proteins (Chapter 4).  Furthermore, we have shown that SUMO 
conjugation negatively modulates the intrinsic activity of TopoIIα in vitro, 
implicating a role for TopoIIα SUMOylation in chromosome segregation (Chapter 
3).  We found that Lys 660 is a SUMOylation site of TopoIIα and may be 
completely responsible for the SUMOylation-dependent regulation of TopoIIα 
activity (Chapter 3).  We also determined that PARP1 is a target for SUMO2/3 
conjugation  during mitosis and is SUMOylated in a PIASy-dependent manner 
(Chapter 2).  Finally, we have shown that SUMOylation affects PARP1-
dependant PARylation, demonstrating the multiple roles for SUMOylation during 
mitotic progession (Chapter 2).   
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CHAPTER 2 
PIASy mediates SUMO-2/3 conjugation of poly (ADP-ribose) polym-
erase1 (PARP1) on mitotic chromosomes in vertebrates. 
 
Abstract 
PIASy is a SUMO ligase that modifies chromosomal proteins in mitotic 
Xenopus egg extracts, and plays an essential role in mitotic chromosome segre-
gation. We have isolated a novel SUMO-2/3 modified mitotic chromosomal pro-
tein, and identified it as poly (ADP-ribose) polymerase 1 (PARP1). PARP1 was 
robustly conjugated to SUMO-2/3 on mitotic chromosomes, but not on interphase 
chromatin. PIASy promotes SUMOylation of PARP1 both in egg extracts and in 
vitro reconstituted SUMOylation assays. Through tandem mass spectrometry 
analysis of mitotically SUMOylated PARP1, we identified a residue within the 
BRCA1 C-terminal (BRCT) domain of PARP1 (lysine 482) as its primary SUMOy-
lation site. Mutation of this residue significantly reduced PARP1 SUMOylation in 
egg extracts, and enhanced the accumulation of species derived from modifica-
tion of secondary lysine residues in assays using purified components. SUMOy-
lation of PARP1 did not alter in vitro PARP1 enzyme activity, poly-ADP-
ribosylation (PARylation), nor did inhibition of SUMOylation of PARP1 alter the 
accumulation of PARP1 on mitotic chromosomes, suggesting that SUMOylation 
regulates neither the intrinsic activity of PARP1 nor its localization. However, loss 
of SUMOylation increased PARP1-dependent PARylation on isolated chromo-
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somes, indicating SUMOylation controls the capacity of PARP1 to modify other 
chromatin-associated proteins.  
 
Introduction 
 
Small Ubiquitin-related Modifiers (SUMOs) are proteins found in all eu-
karyotes that become covalently conjugated to other cellular proteins in a manner 
similar to ubiquitination (5,64). This modification (SUMOylation) regulates many 
aspects of interphase nuclear function and structure (64-66), as well as events 
during mitosis (41). Consistent with the important and broad roles of the SUMOy-
lation pathway, hundreds of SUMOylation targets have been identified in proteo-
mic screens (51,67-69). Three major SUMO family proteins, called SUMO-1, 
SUMO-2 and SUMO-3, are expressed in vertebrates. SUMO-2 and SUMO-3 are 
closely related in their primary sequence (95% identical), whereas SUMO-1 is 
around 45% identical to either of the other two paralogues. In contexts where 
SUMO-2 cannot be functionally distinguished from SUMO-3, we will refer to 
these paralogues collectively as SUMO-2/3. All vertebrate paralogues are around 
50% identical to the single SUMO protein found in budding yeast, Smt3p (5). 
SUMO conjugation to cellular substrates is carried out in a manner similar to 
Ubiquitin. The conjugation process requires three sequential enzymes: an acti-
vating (E1) enzyme, a conjugating (E2) enzyme and usually a SUMO ligase (E3 
enzyme). All SUMOylation utilizes the same E1 and E2 enzymes, which are 
called Uba2/Aos1 and Ubc9, respectively. However, there are a number of differ-
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ent E3 enzymes that show a high degree of specificity for particular conjugation 
targets (64).  
All eukaryotes possess E3 enyzmes with variant RING-finger like domains 
(SP-RINGs) (64). These proteins are called Siz (SAP and miz-finger domain) 
proteins in yeast and PIAS (protein inhibitor of activated STAT) proteins in verte-
brates. The five vertebrate PIAS proteins (PIAS1, PIAS3, PIASxα, PIASxβ and 
PIASy) are involved in a wide variety of processes, including signal transduction, 
gene expression and genome maintenance (70). We have previously shown that 
PIASy-mediated conjugation of SUMO-2/3 to mitotic chromosomal proteins is es-
sential for proper chromosomal segregation at anaphase in Xenopus egg extract 
(XEE) cell free assays (8). One of the major targets for PIASy-directed SUMOyla-
tion is DNA topoisomerase IIα (TopoIIα) (71). PIASy deficient mice are viable 
(72), suggesting PIASy-catalyzed SUMOylation is not essential during anaphase 
in mice. However, siRNA-mediated PIASy knock down causes mitotic arrest with 
aberrant chromosome cohesion in HeLa cells (73). Moreover, the yeast Siz1p 
and Siz2p proteins are essential for accurate segregation of chromosomes in 
yeast (28). It thus appears that PIASy-mediated SUMOylation plays an essential 
role in regulating mitotic chromosomal structure and progression of mitosis in 
many cellular contexts. 
Poly-ADP-ribosylation (PARylation) of proteins is another major post-
translational modification of many nuclear proteins, catalyzed by Poly-ADP-
ribosyl Polymerases (PARPs) (34,74,75). All PARPs share a conserved catalytic 
domain that interacts with NAD+, which is the donor molecule of poly(ADP-
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ribose) (76). The importance of PARylation during mitosis has been demon-
strated: Inhibition of PARylation compromises spindle formation in XEEs (77). 
PARylation mediated by the enzyme Tankyrase-1 has been particularly impli-
cated the correct assembly of spindle poles (78). Another PARylation enzyme, 
PARP1, has been shown to interact with centromeres and could mediate PARy-
lation of centromeric proteins (79,80). PARP1 interacts with the mitotic chromo-
somal protein kinase, Aurora B, and could mediate PARylation of Aurora B to 
regulate its activity (38). Although the mitotic function of PARP1 has not been 
clearly demonstrated, the increasing evidence that PARP1 plays a role in chro-
matin structure suggests the potential relevance of PARP1 activity to chromoso-
mal structure and function in mitosis (75,81). 
We identified PARP1 as a SUMO-2/3 modified substrate associated with 
mitotic chromosomes. PARP1 was robustly conjugated to SUMO-2/3 on mitotic 
chromatin, but not on interphase chromatin. PIASy promoted PARP1 SUMOyla-
tion both in XEEs and in vitro SUMOylation assays using purified, recombinant 
proteins. Through tandem mass spectrometry analysis of mitotically SUMOylated 
PARP1, we identified a residue within the BRCA1 C-terminal (BRCT) domain of 
PARP1 (lysine 482) as its primary SUMOylation site. Mutation of this residue sig-
nificantly reduced PARP1 SUMOylation in XEEs, and enhanced the accumula-
tion of species derived from modification of secondary lysine residues in assays 
using purified components. SUMOylation of PARP1 did not alter PARP1 auto-
PARylation activity in vitro, nor did inhibition of SUMOylation of PARP1 alter the 
accumulation of PARP1 on mitotic chromosomes in XEEs, suggesting that SU-
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MOylation regulates neither the intrinsic activity of PARP1 nor its localization. 
However, loss of SUMOylation increased PARP1-dependent PARylation on iso-
lated chromosomes, indicating SUMOylation controls the capacity of PARP1 to 
modify other chromatin-associated proteins. 
 
Methods 
Recombinant protein expression, Cloning, site directed mutagenesis, and anti-
bodies. 
cDNAs of Xenopus PARP1 were cloned from Xenopus tadpole cDNA 
(kindly provided by T. Amano and Y.B. Shi, NICHD) using PCR amplification with 
addition of the BglII recognition sequence at the 5’end and SalI recognition se-
quence at the 3’end. Amplified cDNA was subcloned into pEGFP-C1 plasmids 
using BglII and SalI sites and was verified by DNA sequencing. The full-length 
cDNAs were subcloned into pET28 using BamH1 and XhoI restriction sites.  
cDNA fragments encoding Xenopus PAPR1 (amino acids 1-150 ; PARP1xl-N and 
500-650; PARP1xl-M) were amplified from a pEGFP-PARP1construct and were 
subcloned into pGEX4T-1(GE-Healthcare) and pET28a (Novagen) using BamHI 
and XhoI restriction sites. The recombinant proteins encoded by these cDNAs 
were expressed in E. coli and purified by tag-based purification according to the 
manufacture’s protocol, followed by conventional ion-exchange chromatography. 
The Lysine to Argenine substitution of PARP1 was produced by site-directed 
mutagenesis (Quick change, Stratagene) according to the manufacture’s proto-
col.  
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Polyclonal antibodies against PARP1 and TopoIIα were generated in rab-
bits by injection with recombinant fragments of His6-T7-PAPR1xl-N, His6-T7-
PAPR1xl-M, and His6-T7-TopoIIαxl C-terminal (amino acids 1359-1579) respec-
tively. The rabbit antisera were subjected to affinity purification on NHS-
Sepharose (GE-Healthcare) columns with their covalently bound antigens. The 
anti-SUMO-2/3 polyclonal Guinea Pig antibody was raised and purified similar to 
previous polyclonal rabbit antibody (71). The anti-PAR monoclonal antibody and 
anti-T7 tag antibody conjugated with HRP were purchased from Trevigen and 
EMD bioscience, respectively. Unless otherwise specified, other reagents were 
obtained from Sigma-Aldrich Chemical Company. 
 
Protein purification and in vitro SUMOylation assay. 
The recombinant E1 complex (Aos1/Uba2 heterodimer) was purified by 
co-expression His6-Aos1 and Uba2 (kindly provided by Dr. F. Melchior) in E. coli 
as described previously (54).  The bacterially expressed E1 complex was purified 
with Talon affinity resin (Clontech) purification followed by SUMO affinity and 
conventional chromatography as previously described (82). Purification of re-
combinant SUMO-2, wild type Ubc9, dnUbc9 and PIASy were as previously de-
scribed (8,71). 
Recombinant PARP1wt and PARP1K482R proteins were expressed in 
BL21(DE3) at 15 °C in the presence of 5% Glycerol, 2.5% Ethanol and 0.1mM 
ZnCl2. The expressed proteins were purified from the soluble fraction of the bac-
terial lysate using Talon affinity resin (Clonetech), followed by Sephacyryl-300 gel 
 40 
filtration and SP-Sepharose column chromatography (GE Healthcare). Purified 
PARP1 proteins were concentrated up to 2~3 mg/ml by centrifugal concentrator 
(Amicon Ultra-4, 30kDa, Millipore) then snap frozen by liquid N2 in small aliquots.  
In vitro SUMOylation assay was performed with 15nM E1, 5mM SUMO-2, 
2.5mM ATP, and 500nM PARP1 in reaction buffer (20mM Tris (pH7.5), 50mM 
NaCl, 10mM MgCl2, 0.05% Tween 20 and 0.5mM DTT) together with the indi-
cated Ubc9 (E2) and PIASy (E3) concentrations. Reactions were incubated at 25 
C° for the indicated periods. 
Xenopus egg extracts. 
Sperm chromatin and low-speed extracts of Xenopus eggs arrested in 
metaphase by CSF were prepared as described (63). Where required, CSF ex-
tracts were driven into interphase by the addition of 0.6 mM CaCl2. For mitotic 
chromosome assembly or interphase nuclear assembly, demembranated sperm 
chromatin were added to CSF or interphase extracts, and incubated for 40~60 
minutes at room temperature. Chromatin isolation was performed as previously 
described (71). Unless otherwise specified, all reactions contained 5,000 sperm 
nuclei per µl.  
 
Immunodepletion and immunofluorescence. 
The immunodepletion experiment with XEE was performed as previously 
described (8) with an affinity purified anti-PARP1 antibody. For add-back experi-
ments, recombinant PARP1 proteins were added at an endogenous concentra-
tion at 4 µg/ml.  
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The immunofluorescence analysis in Figure 5C was demonstrated as pre-
viously described (8). In brief, 100 µl of CSF extracts were released into inter-
phase by 0.6 mM CaCl2 addition. 200 sperm/µl were added 5 minutes after the 
CaCl2, and the extracts were incubated at 23˚C for 55 minutes to complete DNA 
replication. Re-entry into mitosis was induced by the addition 50 µl of fresh CSF 
extract. In the case of inhibition of mitotic SUMOylation, dnUbc9 (150 ng/µl final 
concentration) was also added at this point. The reactions were incubated for 40 
minutes after the addition of fresh CSF extract to reach metaphase. Then 50 µl 
were removed from each reaction, diluted with 200 µl of buffer A (0.8x CSF-XB 
buffer, containing 10 mM β-Glycerolphosphate and 250 mM sucrose), and incu-
bated for 5 min at 23˚C. 300 µl of buffer A containing 4% paraformaldehyde was 
added to this sample and incubated for an additional 10 minutes. Samples were 
spun onto cover slips through a 35% glycerol cushion. Chromosomal samples on 
cover slips were post-fixed by 1.6% paraformaldehyde and processed for immu-
nostaining with anti-PARP1 (rabbit polyclonal), -SUMO-2/3 (guinea pig poly-
clonal), and -CENP-A (chicken polyclonal). Anti-rabbit Alexa 568, anti-guinea pig 
Alexa 684 and anti-chicken Alexa 488 were used as secondary antibodies re-
spectively. Specimens were observed by Nikon TE2000-U microscope with Plan 
Apo 100x/1.40 objective. Images were taken with Retiga SRV CCD camera (Qi-
mageing) operated by Volocity software (Improvision).  
 
PARylation assay 
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 To measure PARylation activity of in vitro SUMOylated PARP1, reactions 
of in vitro SUMOylation were incubated for 60 minutes and then the reactions 
were diluted twice with the reaction buffer (same as in vitro SUMOylation reaction 
buffer) containing 2mM NAD+. The reactions were incubated further at 25°C for 
indicated periods. Termination of reaction was done by addition of SDS-PAGE 
sample buffer to the reaction mixture. For analysis of PARylation of chromosomal 
proteins, the mitotic chromosomes, assembled in XEE reaction, were suspended 
into 30 ul of the reaction buffer containing 1mM NAD+ and incubated at room 
temperature for 10 minutes. The reactions were centrifuged and chromosomal 
pellets were boiled in SDS-PAGE sample buffer. PARylation of proteins in SDS-
PAGE samples were determined by immunoblotting with anti-PAR monoclonal or 
polyclonal antibodies (Trevigen).  
 
Results 
PIASy-mediates SUMO-2/3 conjugation of PARP1 on mitotic chromosomes. 
PIASy-mediated SUMO-2/3 modification of chromosomal proteins is es-
sential for faithful anaphase chromosome segregation in the Xenopus egg extract 
(XEE) in vitro system (8). There are a number of readily detectable SUMOylated 
proteins on mitotic chromosomes in XEEs whose modification requires PIASy, 
including Topoisomerase-IIα (TopoIIα) (8). To identify the full spectrum of mitotic 
SUMOylation substrates for PIASy in XEEs, we added Hexa-Histidine (His6)-
tagged SUMO-2 protein to XEEs arrested in meiotic M phase through the action 
of cytostatic factor (CSF XEEs) in the presence of demembranated sperm chro-
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matin. We purified a chromosomal fraction from these reactions and isolated the 
SUMOylated proteins by Co2+ affinity chromatography under denaturing condi-
tions (Figure 2.2), in a manner analogous to earlier studies (71). We observed a 
prominent SUMOylated species, with a molecular weight around 140kDa, and 
subjected it to LS-MS/MS analysis for protein identification at the Harvard Micro-
chemistry & Proteomics Facility (Cambridge, MA). The results indicated that this 
species was SUMO-2-conjugated poly (ADP-ribose) polymerase1 (PARP1). To 
confirm this identification, we cloned Xenopus laevis PARP1, and prepared anti-
bodies against fragments of the PARP1 protein (Figure 2.1D). Immunoblotting 
analysis of mitotic chromosomes prepared from CSF XEEs clearly showed more 
slowly migrating forms of PARP1 protein, which were abolished when a dominant 
negative form of Ubc9 (dnUbc9 (8)) was added to the reactions, or increased in 
abundance upon addition of exogenous PIASy (Figure 2.1A).  
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Figure 2. 1 
PARP1 is a PIASy-mediated SUMOylated protein on mitotic chromosomes.  
A) PARP1 is SUMOylated on mitotic chromosomes. Chromosomal fractions 
were prepared in CSF extracts in the presence of either dnUbc9 or PIASy as de-
scribed in Materials and Methods. Isolated chromosomes were analyzed by im-
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munoblotting with indicated antibodies.  Arrows indicate the position of SUMOy-
lated PARP1, which were diminished when SUMOylation was inhibited by 
dnUbc9. B) PIASy is required for PARP1 SUMOylation. CSF extracts were 
subjected to immunodepletion with anti-PIASy antibody (-PIASy), and then a pu-
rified recombinant PIASy was supplemented to PIASy-depleted extracts (-
PIASy+Rec.PIASy). Chromosomal fractions were prepared in the indicated con-
ditions of CSF extracts, then the SUMOylation status of isolated chromosomes 
was analyzed with the indicated antibodies. Arrows indicate the position of SU-
MOylated PARP1. C) PARP1 SUMOylation is specific in mitosis. CSF extracts 
were released into interphase by addition of CaCl2. Sperm nuclei were added to 
either CSF or interphase extracts. After incubation of the indicated periods with 
interphase extracts or 40 minutes with CSF extracts, the chromatin fractions 
were isolated as described in Materials and Methods.  Isolated chromatin frac-
tions were subjected to immunoblotting with the indicated antibodies. Arrows in-
dicate SUMOylated PARP1. D) Representation of functional domains of 
PARP1 (adjusted from (75)). Lines indicate the fragments of PARP1 that were 
used as antigens. 
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Figure 2. 2 
Purification of novel SUMO-2 modified proteins from mitotic chromosomes. 
Mitotic chromosomes were prepared with the CSF extract with or without His6-
SUMO-2. After sixty minutes of incubation, the mitotic chromosomes were sepa-
rated by centrifugation (Chromatin). Chromosomal proteins were extracted in a 
buffer containing 8.5M urea (Urea Extract), and the recovered fractions were 
subjected to further purification using metal affinity chromatography. Aliquots 
from unbound fractions and eluted fractions were analyzed by immunoblotting 
with an anti-SUMO-2/3 antibody together with Chromatin and Urea extract frac-
tions (Left panel). Proteins in the elution from the His6-SUMO-2 containing sam-
ple were analyzed by silver staining (Right panel). Arrows indicate the isolated 
His6-SUMO-2 modified protein, which was subjected to identification by LS-
MS/MS analysis. 
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To test directly whether the SUMOylation of PARP1 requires PIASy, we 
depleted PIASy from CSF XEEs (Figure 2.1B); PIASy depletion eliminated the 
slowly migrating SUMOylated forms of PARP1. These forms of PARP1 were re-
stored upon the addition of a recombinant PIASy to the depleted CSF XEEs, con-
firming that they arise in a PIASy-dependent manner. To test whether SUMOyla-
tion of PARP1 was sensitive to the cell cycle status of the XEE, we compared 
chromatin fractions isolated from CSF XEEs to chromatin fractions from inter-
phase XEEs (Figure 2.1C). Immunoblotting analysis with anti-PARP1 and anti-
SUMO-2/3 antibodies showed robust SUMOylation in the CSF XEEs (indicated 
with arrows), as expected, but no SUMOylated PARP1 could be detected in the 
interphase chromatin fractions. Together, these results show that PARP1 is a 
target of mitotic, PIASy-mediated SUMO-2/3 conjugation that is associated with 
mitotic chromosomes in XEEs. Notably, this pattern was closely similar to the 
SUMOylation of TopoIIα, an established PIASy substrate in this system (71). 
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Figure 2. 3 
PIASy stimulate PARP1 modification by SUMO-2/3 in reconstituted in vitro 
SUMOylation reaction. 
All recombinant proteins, E1, E2, E3, PARP1 and SUMO, were expressed in E. 
coli and purified as described in Materials and Methods. In vitro SUMOylation re-
action was performed with 15nM E1, 500nM PARP1 and 6µM of SUMO at 25°C. 
Reactions were terminated at the indicated times by the addition of SDS-PAGE 
sample buffer. SUMOylation of PARP1 was analyzed by immunoblotting with 
HRP-conjugated anti-T7 antibody (Novagen). The bracket indicates the position 
of SUMOylated PARP1. A) Ubc9 dose dependency of PARP1 SUMOylation 
without E3. B) Kinetics of Ubc9 dependent PIASy SUMOylation. The SU-
MOylation reaction was performed with the indicated concentration of Ubc9 with-
out PIASy. The reaction mixtures were incubated for 60 minutes in A) and for the 
indicated time periods in B). C) PIASy dependent SUMOylation of PARP1. The 
reaction mixtures containing the indicated concentration of Ubc9 and PIASy were 
incubated for the indicated times.  
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In vitro reconstitution of PARP1 SUMOylation by PIASy.  
To examine PARP1 SUMOylation by PIASy further, we reconstituted this 
modification in an in vitro system using entirely purified components, which were 
expressed in bacteria and prepared as described in the Experimental Procedures 
section. We found that PARP1 could be modified by SUMO-2/3 in the absence of 
PIASy in reactions containing a very high concentration of Ubc9 (600 nM) (Figure 
2.3A indicated with brackets). These concentrations significantly exceeded the 
physiological concentration of Ubc9 in XEEs, which was determined to be around 
30 nM through quantitative immunoblotting of XEE in comparison to purified re-
combinant Ubc9 (data not shown). In reactions containing 30 nM Ubc9, SUMOy-
lated PARP1 was hardly detected (Figure 2.3B), even with prolonged incubation. 
Notably, strong SUMOylation of PARP1 was observed when PIASy was added to 
reactions containing near-physiological concentrations of Ubc9 (Figure 2.3C). 
Modified forms of PARP1 were evident in reactions containing 10 nM Ubc9 and 
15 nM PIASy. Such SUMOylation was enhanced in reactions containing 30 nM 
PIASy. Increasing the concentration of Ubc9 to 30 nM provided a robust boost in 
PARP1 SUMOylation at both concentrations of Ubc9.  
Our results collectively showed that PIASy stimulates SUMOylation of 
PARP1 at physiological concentrations of Ubc9. A subtler but equally important 
finding from these in vitro reactions was that the pattern of SUMOylated PARP1 
bands differed between the reactions with and without PIASy. Without PIASy, we 
observed a SUMOylated form of PARP1 with an aberrant migration on SDS-
PAGE that did not correspond to the bands observed in CSF XEEs (indicated 
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with asterisk in Figure 2.3A and B). This form was dramatically decreased in PI-
ASy-dependent reactions (compare Figure 2.3B and C). In other words, the pat-
tern of SUMOylated PARP1 species found in the PIASy-dependent in vitro reac-
tions (Figure 2.3C) was much closer to the pattern observed within the chromatin 
fractions of complete CSF XEEs.  
 
Lysine 482 is a primary SUMOylation site of PARP1. 
To determine the function of PARP1 SUMOylation, we mapped its SU-
MOylation site(s). We isolated SUMOylated PARP1 by immunoprecipititation with 
anti-PARP1 antibodies under denaturing conditions from a mitotic chromatin frac-
tion made from CSF XEEs (Figure 2.4A) (83). Both SUMOylated and non-
SUMOylated PARP1 were subjected to MS/MS analysis for mapping of SUMOy-
lation site(s). The SUMOylation site was identified by mass spectrometry follow-
ing a double digestion with trypsin and chymotrypsin. Chymotrypsin generated a 
signature QQQTGG tag on the modified lysine of PARP1. With over 70% of se-
quence coverage of PARP1, this analysis indicated that Lysine 482 was a candi-
date SUMOylation site on PARP1. Moreover, alignment of Xenopus laevis 
PARP1 primary sequence to Homo sapiens PARP1 (Figure 2.4B) indicated that 
Lysine 482 is conserved to a recently reported SUMOylation site of human 
PARP1, which was found by mutational analysis (84).  
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Figure 2. 4 
Mapping of SUMOylation site of PARP1 by MS/MS. 
Chromosomal proteins were isolated by denaturing buffer containing SDS from 
mitotic chromosomes that were assembled in the indicated condition of CSF ex-
tracts. After renaturation with buffer containing thesit, extracted fractions were 
subjected to immunoprecipitation with affinity purified anti PARP1 antibody. Pre-
cipitated fractions were separated by SDS-PAGE. Both SUMOylated (asterisk) 
and non-SUMOylated PARP1 (arrow head) were subjected to MS/MS analysis 
for mapping SUMOylation site. The SUMOylation site was identified by mass 
spectrometry following a double digestion with trypsin and chymotrypsin. The 
Chymotrypsin is responsible for generating the QQQTGG signature tag on the 
modified lysine which was observed for PARP1. MS/MS analysis indicates the 
Lysine at 482 as a candidate site of SUMOylation with over 70% of sequence 
coverage of PARP1. B) The diagram shows the comparison of primary se-
quences of Xenopus laevis PARP1 (PARP1 xl) and Homo sapience PARP1 
(PARP1 hs) around the identified SUMOylation sites. The bold and underlined 
letter indicates lysine 482, the mapped candidates site of SUMOylation.  
 
 
To confirm this mapping result, we introduced a mutation at Lysine 482 to 
encode an Arginine at this position (PARP1-K482R). We compared the SUMOy-
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lation patterns of wild type PARP1 (PARP1-wt) and PARP1-K482R within SU-
MOylation assays using recombinant proteins. In the absence of PIASy, PARP1-
wt and PARP1-K482R became SUMO-2/3 conjugated to similar extents, and 
showed similar dependence upon the concentration of Ubc9 (Figure 2.5A). How-
ever, PARP1-K482R showed a much greater accumulation of the aberrant SU-
MOylation product that was preferentially observed in PIASy-independent reac-
tions (Figure 2.5A, indicated with arrow. Compare to Figure 2.3).  
In reactions containing PIASy, there were two important differences be-
tween PARP1-K482R and PARP1-wt (Figure 2.5B). First, PARP1-K482R 
showed a significantly lower efficiency of SUMOylation than PARP1-wt. For in-
stance, more than 50% of PARP1-wt became SUMOylated within 60 minutes at 
the lowest Ubc9 and PIASy concentrations (10 nM and 15 nM, respectively), 
whereas the extent of PARP1-K482R SUMOylation was much less under the 
same conditions. In the presence of 30 nM Ubc9 and 30 nM PIASy, the de-
creased efficiency of PARP1-K482R SUMOylation was even more obvious; 
PARP1-wt was almost 100% SUMOylated within 30 minutes, while PARP1-
K482R was only about 50% SUMOylated in the same interval. Second, aber-
rantly migrating SUMOylated species were more abundant in reactions contain-
ing PARP1-K482R (Figure 2.5B. Indicated by arrow). As before, these forms 
were largely suppressed by the presence of PIASy in reactions containing 
PARP1-wt (Figure 2.5B, Figure 2.3). Collectively, these results indicate that Ly-
sine 482 is a primary SUMOylation site of PARP1 for PIASy-mediated SUMO-2/3 
modification in vitro. Mutation of this residue is accompanied by the enhanced 
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modification of other lysines within PARP1, leading to the formation of species 
with electrophoretic motilities that differ from the primary SUMOylation products 
observed in intact CSF XEEs. 
 
 
 
Figure 2. 5 
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The substitution of Lysine 482 to Arginine causes an alteration in the effi-
ciency and specificity of the SUMOylation of PARP1 in in vitro SUMOylation 
assay. We have introduced a mutation at lysine 482 to arginine (PARP1 K482R) 
to confirm the mapping result. Purified PARP1 proteins were subjected to in vitro 
SUMOylation assay as in Figure 2.3. A) Ubc9 dose dependent reaction with-
out PIASy. The SUMOylation reaction was performed with the indicated concen-
tration of Ubc9 without PIASy. The reaction mixtures were incubated for 60 min-
utes. B) PIASy-dependent reaction. The reaction mixtures containing the indi-
cated concentration of Ubc9 and PIASy were incubated for the indicated times. 
The arrow indicates the aberrant molecular weight shifted form that is more 
abundant in K482R mutant than the wild type. 
 
PARP1-K482R shows deficient SUMOylation in XEE assays 
We wished to compare the SUMOylation of PARP1-K482R to PARP1-wt 
under more physiological conditions in XEE CSF extracts. We added recombi-
nant, T7-tagged PARP1-K482R and PARP1-wt to chromatin-containing CSF 
XEEs that had been immunodepleted of endogenous PARP1 using anti-PARP1 
antibodies (-PARP1) (Figure 2.6). The efficiency of depletion was measured by 
immunoblotting the extracts with an anti-PARP1 antibody (Left panel, indicated 
as Extracts). More than 99% of PARP1 was eliminated from CSF XEEs without 
detectable changes in the concentration of another PIASy substrate, TopoIIα. Af-
ter a 60 minute incubation, mitotic chromosomes were prepared from these reac-
tions and the chromosomal proteins were isolated (Figure 2.6, right panels). As 
expected, chromosomes prepared from the PARP1-depleted extract did not con-
tain detectable levels of PARP1 (Figure 2.6, -PARP1 lane on right panels). Reac-
tions reconstituted through the addition of recombinant PARP1-wt to depleted 
CSF XEEs showed levels of SUMOylation similar to endogenous PARP1 modifi-
cation in non-depleted CSF XEEs (right panels, arrowheads), and this modifica-
tion was similarly sensitive to dnUbc9. On the other hand, PARP1-K482R was 
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SUMOylated to a lesser extent, and the resultant species showed greater elec-
trophoretic mobility than SUMOylated forms of the endogenous protein (Figure 
2.6, indicated with asterisk), as we had previously observed the assays with fully 
purified components (compare Figure 2.5 and 2.6). Notably, the formation of 
these species remained sensitive to dnUbc9. Our findings would be consistent 
with the utilization of an alternative or secondary SUMOylation site(s) in PARP1 
that lacks lysine 482.  
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Figure 2. 6 
Lysine 482 of PARP1 is a primary acceptor site of SUMO-2/3 on mitotic 
chromosomes.  
CSF extracts were immunodepleted with an anti-PARP1-M antibody. Either wild 
type (wt) or K482R mutant PARP1 (K482R) was added to the PARP1-depleted 
extracts. Mitotic chromosomes were assembled with these altered CSF extracts 
 57 
and the chromosomal fractions were isolated. The chromosomal proteins were 
analyzed by immunoblotting with the indicated antibodies. Exogenous PARP1 is 
detected with anti-T7 tag antibody (middle right panel). Arrowhead indicates SU-
MOylated PARP1 corresponding to the endogenous SUMOylated PARP1. Aster-
isk indicates a shifted PARP1 that does not correspond to the endogenous SU-
MOylated PARP1 and was observed only with K482R. 
 
 
SUMOylation regulates PARP1 activity on chromosomes. 
Lysine 482 is located within the BRCT domain of PARP1. This domain is 
predicted to bind to other proteins, as well as to mediate auto-PARylation. There-
fore, we hypothesized that SUMOylation of K482 may either affect auto-
PARylation activity by modulating the conformation of the catalytic domain or af-
fect the PARylation of other substrates by modulating PARP1’s protein-protein 
interactions (75,76).  
To test the first possibility, we examined whether SUMOylation of PARP1 
altered auto-PARylation activity in an in vitro reaction. An in vitro SUMOylation 
reaction was performed in the presence of PIASy as in Figure 2.5B, using either 
unconjugatable SUMO-2 that lacked a C-terminal diglycine motif (SUMO-2-G) or 
conjugatable SUMO-2 (SUMO-2-GG). As expected, there was no SUMOylated 
PARP1 detected in the SUMOylation reaction with SUMO-2-G, while the bulk of 
PARP1 was modified in the reaction with conjugatable SUMO-2-GG (Figure 
2.7A, lower panel at t = 0 min) (82). After PARP1 had become SUMOylated, 
NAD+ was added to the reaction, and further incubation allowed the formation of 
poly(ADP-ribosyl) chains on PARP1. Poly(ADP-ribosyl) chain formation was ana-
lyzed by immunoblotting with a monoclonal anti-PAR antibody (Figure 2.7A upper 
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panel). There was a similar amount of PARylated PARP1 in both SUMO-2-G- 
and SUMO-2-GG- containing reactions. These results indicate that SUMOylated 
PARP1 retains robust auto-PARylation activity. Our findings suggest that SU-
MOylation of PARP1 has neither an inhibitory nor an enhancing effect on the 
auto-PARylation of PARP1.  
To test the second possibility, we examined whether inhibition of SUMOy-
lation in XEE assay affects a PARylation on chromosomal proteins in CSF XEEs 
(Figure 2.7B). We prepared mitotic chromosomes under conditions where SU-
MOylation occurred normally, and under conditions where it was blocked by 
dnUbc9. We then induced PARylation of chromosomal proteins by incubating the 
isolated chromosomes with NAD+ as described in experimental procedures. The 
PARylation of chromosomal proteins was analyzed by immunoblotting with anti-
PAR polyclonal antibody. As shown in Figure 2.7B, the chromosomes from the 
reaction where SUMOylation was inhibited (+dnUbc9 lane) showed more PARy-
lation, and the pattern of PARylated proteins was clearly different from the control 
reaction (control lane). To confirm that this PARylation was dependent upon 
PARP1, we performed the same experiment using CSF XEEs that were depleted 
of PARP1. The PARP1-depleted chromosomes showed little PARylation, indicat-
ing that PARP1 was the primary enzyme that mediated chromosomal PARylation 
in this assay.  
Finally, we investigated whether SUMOylation may control PARylation by 
modulating PARP1 localization on mitotic chromosomes. Sperm chromatin was 
allowed to undergo a single round of DNA replication in interphase XEEs. The 
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XEEs were then returned to mitosis through addition of a fresh aliquot of CSF 
XEE, allowing the formation of mitotic chromosomes. Individual chromosomes 
were isolated on cover slips and stained using antibodies against SUMO-2/3, 
PARP1 and centromeric histone variant CENP-A (Figure 2.7C). Consistent with 
earlier experiments (8), the anti-SUMO2/3 antibody stained the inner centromere 
region (ICR) of the chromosomes and this signal was completely abolished in the 
presence of dnUbc9 (Figure 2.7C right panels). PARP1 associated broadly on 
chromosome arms, with slight accumulation on ICR, partially co-localizing with 
the region of highest SUMO-2/3 accumulation (Figure 2.7C upper/left panel). As 
shown in the magnified insets, red (PARP1) and green (SUMO-2/3) merged to 
yellow at the edge of SUMO-2/3 signals although majority of SUMO-2/3 signals 
did not overlap with PARP1. This pattern was not obviously changed by the addi-
tion of dnUbc9, arguing against the possibility that SUMO-dependent changes in 
PARylation by PARP1 are due to its mislocalization on chromosomes. Together, 
our findings favor the possibility that SUMOylation primarily controls the capacity 
of PARP1 to act on PARylation substrates, without substantially altering its intrin-
sic enzymatic activity or subcellular localization. 
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Figure 2. 7 
Inhibition of SUMOylation on mitotic chromosomes alters chromosomal 
PARylation. 
 61 
A) SUMOylated PARP1 retains robust enzymatic activity of poly(ADP-
ribosyl)ation in vitro. An in vitro SUMOylation reaction was performed in the 
presence of the indicated SUMO-2 proteins as in Figure 2.3. After the SUMOyla-
tion reaction, NAD+ was added to the reaction mixture and then the reaction mix-
ture was incubated for the indicated periods. Poly(ADP-ribosyl) chain formation 
was analyzed by a monoclonal anti-PAR antibody (Trevigen). PARP1 was de-
tected with an anti-T7 antibody.  
B) SUMOylation affect PARylation on chromosomes prepared from XEE. 
Mitotic chromosomes were isolated from the extracts that were manipulated as 
indicated. Isolated chromosomal fractions were incubated with NAD+ containing 
buffer to promote PARylation on chromosomal proteins, and then the reactions 
were terminated with the addition of SDS-PAGE sample buffer. The obtained 
chromosomal samples were analyzed by immunoblotting with the indicated anti-
bodies. The bracket indicates the area of PARylation signals affected by the inhi-
bition of SUMOylation. 
C) Inhibition of SUMOylation does not affect in the localization of PARP1 on 
mitotic chromosomes significantly. 
CSF extracts were released into interphase by CaCl2 addition. 200 sperm/µl were 
added 5 minutes after CaCl2 and the extract was incubated at 23˚C for 55 min-
utes. Re-entry into mitosis was induced by addition of fresh CSF extract (50% of 
reaction volume) with or without dnUbc9 (150 ng/µl final concentration). Chromo-
somes from each reaction were spun onto cover slips and analyzed by im-
munofluorescence with antibodies against SUMO-2/3, PARP1, and CENP-A as 
described in material and methods. Each signal was pseudo colored as indicated 
at the top of the panels. DNA was visualized with Hoechst 33342 staining. Insets 
are magnified images around the centromere region. 
 
 
Discussion 
We have identified PARP1 as a novel mitotic SUMO-2/3-modified chro-
mosomal substrate in M-phase Xenopus laevis egg extracts (CSF XEEs). In a 
manner similar to a previously identified SUMO-2/3 conjugation target, DNA 
topoisomerase IIα, PARP1 modification in CSF XEEs required PIASy, the pres-
ence of chromatin and the mitotic phase of the cell cycle (8,71). We have 
mapped the SUMOylated residues of PARP1 that was purified from mitotic 
chromosomes, and found that Lysine at 482 was a primary SUMOylation site. 
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We have reconstituted SUMOylation of PARP1 using purified components, and 
shown that PIASy plays two important roles in its conjugation: It enhances both 
the efficiency of SUMOylation and the accuracy of site selection. At high concen-
trations of Ubc9, PARP1 could be SUMOylated in the absence of PIASy. At more 
physiological concentrations of Ubc9, however, PARP1 SUMOylation became 
almost entirely PIASy-dependent. The aberrant migration of the modified species 
in reactions lacking PIASy suggested that secondary or tertiary SUMOylation 
site(s) on PARP1 were being used at a greater frequency than when it was pre-
sent. Similar species were observed even in the presence of PIASy when the re-
actions were performed with a PARP1 mutant, PARP1-K482R, which lacked the 
major SUMOylation site that we had mapped.  
 
Control of chromosomal PARylation by SUMOylation 
We did not find that PARP1 activity in auto-PARylation assays was sub-
stantially dependent upon its SUMOylation status (Figure 2.7A), arguing against 
the idea the SUMOylation of PARP1 changes its intrinsic enzymatic activity. On 
the other hand, we observed that PARP1 was the major PARylation enzyme as-
sociated with mitotic chromosomes in XEEs, since this modification was essen-
tially abolished in its absence, and that its capacity to mediate PARylation of 
other chromosomal proteins was enhanced under conditions where SUMOylation 
was suppressed (Figure 2.7B).  
These data are consistent with the idea that SUMOylation of PARP1 sub-
stantially decreases its capacity to recognize or modify other proteins. Since Ly-
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sine 482 is located within the BRCT domain of PARP1, we speculate that SU-
MOylation of this residue may substantially change PARP1 association with other 
proteins (85). Such interactions did not appear to be important for targeting of 
PARP1 onto mitotic chromosomes (Figure 2.7C), but may disrupt its capacity to 
PARylate its chromatin-bound substrates. An alternative explanation for our find-
ings is that SUMOylation inhibits PARylation through modification of PARP1 tar-
get proteins. The dnUbc9 would thus increase PARylation by relieving such inhi-
bition. It has not been possible to restore chromosomal PARylation to PARP1-
depleted XEEs with recombinant PARP1, possibly because immunodepletion of 
PARP1 co-precipitates other factors necessary for its activity (data not shown), 
so it has not been possible to rigorously test these two alternatives; notably they 
are not mutually exclusive, so that SUMOylation of both PARP1 and its targets 
could modulate the level of chromosomal PARylation.  
Further investigation will be required to identify the substrates of PARP1-
mediated PARylation in XEEs and the role of this modification in altering their 
function. Consistent to our finding that a portion of PARP1 localizes on ICR with 
XEE assay (Figure 2.7C), PARP1 is localized to the centromeres of mammalian 
cells (79,86). It has been shown to be involved in the regulation of chromatin 
structure (87) and to promote the PARylation of several centromeric proteins 
(80). One attractive possibility is that these aspects of PARP1 function might be 
regulated through SUMOylation. In this context, the Aurora B kinase is a particu-
larly intriguing potential target for PARP1; it interacts with the BRCT domain of 
PARP1 and can be PARylated by PARP1 (38). Moreover, the fact that PARP1 
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associated with the ICR might be consistent with this possibility (Figure 2.7C). 
However, it was not possible for us to validate this notion because we did not find 
evidence that Aurora B becomes PARylated in XEEs, nor that such a modifica-
tion could be modulated by changes in SUMOylation (data not shown). It also 
remains possible that PARP1 itself is a major PARylation substrate on mitotic 
chromosomes. In this case, the capacity of chromosome-bound PARP1 to cata-
lyze auto-PARylation may be more regulated through SUMOylation than isolated 
PARP1 protein in our purified assays (Figure 2.7A). 
 
Role of PIASy  in PARP1 SUMOylation. 
SUMOylation sites of many targets lie within a preferred consensus motif, 
ΨKX(D/E) (Ψ is an aliphatic branched amino acid; X is any amino acid). Ubc9 
can directly bind this motif, and conjugate the lysine residue within it in an E3-
independent manner (88). Lysine 482 of PARP1 lies within such a consensus 
motif (Figure 2.4) and Ubc9 interacts PARP1 in yeast two-hybrid assays (89). 
Consistent with these facts, we found that PARP1 could be SUMOylated in the 
absence of PIASy (Figure 2.3). We note, however, that Ubc9 was also able to 
recognize other lysine residues of PARP1 in these E3-independent reactions, 
since we continued to observe SUMOylation in reactions with a mutant form of 
PARP1 that lacked this residue (PARP1-K482R). Notably, direct recognition by 
Ubc9 is relatively inefficient, and we observed little PARP1 SUMOylation at 
physiological concentrations of Ubc9, even for PARP1 possessing a wild-type 
lysine at residue 482. 
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Recent structural analysis on a fragment of Siz1p, a SIZ/PIAS family 
SUMO ligase from budding yeast, showed that it binds the thioester-linked 
Ubc9~Smt3p complex in such a way as to properly configure it for catalysis and 
to promote correct interactions between the conjugation target and Ubc9’s active 
site (90). PIASy dramatically increased the extent of PARP1 SUMOylation at 
physiological concentration of Ubc9 (Figure 2.3C). This increased SUMOylation 
is likely to reflect the capacity of PIASy to recognize both Ubc9~SUMO-2 and 
PARP1, analogous to the interactions formed by Siz1p. This binding would bring 
them into a single complex, elevating the effective concentration of Ubc9~SUMO-
2, as well as increasing the efficiency of SUMO-2 transfer. Notably, Siz1p also 
directs the transfer of Smt3p to the appropriate lysine residue of the target pro-
tein (90). We find that PIASy can similarly bias conjugation toward a preferred 
residue, Lysine 482. The preference for this residue is not absolute, as we find 
that alternative residues can be utilized when it is mutated, either in purified as-
says (Figure 2.5B) or in XEEs (Figure 2.6), albeit inefficiently.  
 
In summary, we have shown that PARP1 is a substrate of PIASy-
mediated SUMOylation on mitotic chromosomes in XEEs. This modification regu-
lated its activity in this context, perhaps through its capacity to recognize or mod-
ify other chromosomal proteins. PIASy facilitates the modification of PARP1 by 
increasing both the extent of SUMOylation and by directing the modification to a 
preferred site on PARP1. In combination with earlier observations showing that 
PIASy modifies TopoIIα in XEEs (8,71), our findings suggest that PIASy is re-
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sponsible for a series of coordinated changes in the activity of chromatin-
associated enzymes that contribute to chromosome segregation in this system. 
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CHAPTER 3 
PIASy-dependent SUMOylation regulates  
DNA Topoisomerase IIα activity 
 
Abstract 
 
           DNA Topoisomerase IIα (TopoIIα) is an essential chromosome-associated 
enzyme with activity implicated in the resolution of tangled DNA at centromeres 
prior to anaphase onset. However, the regulatory mechanism of TopoIIα activity 
is not understood. Here we show that PIASy-mediated SUMO2/3 modification of 
TopoIIα strongly inhibits TopoIIα decatenation activity. Using mass spectrometry 
and biochemical analysis we demonstrate that TopoIIα is SUMOylated at lysine 
660 (Lys660), a residue located in the DNA-gate domain where both DNA cleav-
age and re-ligation take place. Remarkably, loss of SUMOylation on Lys660 
eliminates SUMOylation-dependent inhibition of TopoIIα, indicating that Lys660 
SUMOylation is critical for PIASy-mediated inhibition of TopoIIα activity. To-
gether, our findings provide evidence for the regulation of TopoIIα activity on mi-
totic chromosomes by SUMOylation. Therefore, we propose a novel mechanism 
for regulation of centromeric DNA catenation during mitosis by PIASy-mediated 
SUMOylation of TopoIIα.  
 
Introduction 
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   Resolution of sister chromatid cohesion is a fundamental process required 
for faithful chromosome segregation. Together with cohesin-mediated cohesion, 
DNA catenation maintains chromosome cohesion in the early stages of mitosis 
(91,92). By the onset of anaphase, however, the cohesin complex is removed by 
separase through APC/C-dependent ubiquitination and degradation of securin, 
and the catenation of centromeric DNA is resolved by the action of a specialized 
enzyme called DNA Topoisomerase IIα (TopoIIα) (93,94). A number of early re-
ports showed that TopoIIα relocalizes from chromosome arms to the centromere 
during mitosis (95-97), and further studies using self-primed in situ labeling re-
vealed that catalytically active TopoIIα accumulates primarily at the centromere 
(33). In addition, recent studies have shown that ultrafine bridges originating from 
tangled DNA in metaphase chromosomes were resolved by TopoIIα activity fol-
lowing removal of the cohesin complex (98), indicating a role for TopoIIα activity 
in mitosis. These evidences strongly suggest tight regulation of TopoIIα activity in 
space and time. Although extensive biochemical studies have elucidated the mo-
lecular mechanism of TopoII family proteins’ enzymatic reactions (99), how the 
catalytic activity of TopoIIα is regulated at the centromere in such a specific 
manner is unknown.  
 
 
      Studies examining the relationship between TopoIIα activity and post-
translational modification (PTM) have not clearly demonstrated that TopoIIα ac-
tivity is regulated by PTM (100,101). Yet, one PTM of TopoIIα, SUMOylation, has 
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been suggested as a potential regulator of TopoIIα activity given that TopoIIα 
SUMOylation is mitosis-specific and occurs near centromeres (102). SUMO, a 
small ubiquitin-like modifier, is a conserved ubiquitin family protein in eukaryotes 
(5,64). Vertebrates typically express three SUMO paralogues designated as 
SUMO1, 2, and 3. SUMO2 and 3 are ~95% identical while SUMO1 has ~45% 
identity with both SUMO2 and 3. (In this report, we refer to SUMO2 and 3 as 
SUMO2/3 when they are indistinguishable.)  SUMO proteins contain a C-terminal 
di-glycine motif that is exposed by a hydrolase prior to a SUMOylation reaction of 
target proteins.  The biochemical process of SUMOylation requires unique com-
ponents but is somewhat similar to the ubiquitination pathway.  First, SUMO pro-
teins are activated by the E1 enzyme (Aos1/Uba2 heterodimer); then, they are 
transferred to the E2 enzyme (Ubc9), and finally conjugated to cellular substrates 
via an E3 ligase enzyme. Defects in the SUMOylation pathway have been re-
ported to cause faulty mitosis (41,103), typically represented in most organisms 
by failure of proper chromosome segregation (40,104,105).  
   Siz1p and Siz2p, conserved eukaryotic SUMO E3 ligases, are responsible 
for the SUMOylation of TopoII in budding yeast, and the loss of Siz-mediated 
TopoII SUMOylation decreases chromosome transmission fidelity (28). Using a 
Xenopus Egg Extract (XEE) cell-free assay, we previously showed that PIASy, a 
member of the PIAS/Siz family of SUMO ligases, is an essential chromosomal 
component for promoting TopoIIα SUMO2/3 modification in vertebrates, and 
suggested a role for PIASy in chromosome segregation (8). Moreover, reports 
using HeLa cells revealed that PIASy is required for faithful chromosomal sepa-
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ration, which is not dependent on centromeric cohesin but is related to TopoIIα 
localization at the centromere (73). Together, this evidence indicates that the 
PIAS/Siz family of E3 ligases has a conserved role in chromosome segregation 
in eukaryotes through regulation of TopoII SUMOylation. In contrast, studies us-
ing lysates from mouse embryonic fibroblasts (MEF) that were deficient in 
RanBP2/Nup358, a SUMO E3 ligase that is also a component of the nuclear 
pore complex in vertebrates (54), provided evidence that RanBP2 facilitates SU-
MOylation of TopoIIα through SUMO1 conjugation (106). The discrepancy be-
tween these models remains to be examined.   
     For this report, we established an in vitro SUMOylation assay using re-
combinant TopoIIα as substrate, in order to elucidate the biochemical conse-
quence of PIASy-mediated SUMO2/3 modification on TopoIIα activity.  Consis-
tent with our previous results using XEE assays, we demonstrate that PIASy 
robustly facilitates SUMOylation of TopoIIα, and this modification is SUMO2/3-
specific in vitro.  We also observed that SUMOylated TopoIIα exhibits much less 
DNA decatenation activity, indicating a potential mechanism for inhibition of 
TopoIIα activity by SUMOylation.  Using mass spectrometric analysis of TopoIIα 
isolated from mitotic chromosomes, we identified lysine 660 (Lys660) as a novel 
SUMOylation site of TopoIIα.  Further biochemical studies demonstrated that 
elimination of SUMOylation at Lys660 suppressed SUMOylation-dependent inhi-
bition of TopoIIα activity, independent of other SUMOylation sites.  Finally, we 
show that SUMOylation of Lys660 is stimulated by DNA binding of TopoIIα, sug-
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gesting that the enzymatically active TopoIIα might be a primary target of Lys660 
SUMOylation.  
     Our findings strongly suggest that TopoIIα SUMOylation regulates decate-
nation of centromeric DNA.  The co-localization of TopoIIα and PIASy at centro-
meres, and the stimulation of inhibitory SUMOylation at Lys660 by DNA binding 
of TopoIIα further suggest that this novel regulation of TopoIIα activity is con-
trolled spatiotemporally during mitosis.  Therefore, we propose that the SUMO 
ligase PIASy catalyzes SUMO2/3 modification of TopoIIα that regulates TopoIIα 
activity during mitosis.  
 
Methods 
 
DNA subcloning, site-directed mutagenesis, recombinant protein expres-
sion and purification, and antibodies. The cDNA of TopoIIα was cloned from 
Xenopus laevis tadpole cDNA (kindly provided by T. Amano and Y.B. Shi, 
NICHD) using PCR amplification.  The X. laevis TopoIIα coding sequence was 
subcloned into a pPIC 3.5Kb vector in which either CBP-ZZ, CBP-T7, or T7-ZZ 
tag sequences were inserted.  (The CBP and ZZ TAP-tag plasmids were kindly 
provided by H. Yoon and K. Gould.)  The Lysine to Arginine substitution of 
TopoIIα was generated by site-directed mutagenesis using a QuikChange kit 
(Agilent) according to manufacturer’s protocol.  All constructs were verified by 
DNA sequencing. 
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For preparation of recombinant TopoIIα proteins, the plasmids were transformed 
into the GS115 strain of Pichia pastoris yeast and expressed according to the 
manufacturer’s instructions (Invitrogen).  Protein purification with the CBP and ZZ 
tags was performed using a modified TAP protocol (EMBL Heidelberg).  Briefly, 
yeast cells expressing TopoIIα were frozen and ground with dry ice in a coffee 
mill, and then mixed with lysis buffer (50mM Tris-HCl (pH7.5), 150mM NaCl, 
2mM CaCl2, 1mM MgCl2, 0.1% Triton-X100, 5% Glycerol, 1mM DTT and 10mM 
PMSF).   Samples were then centrifuged at 25,000xg for 40 minutes.  To capture 
the CBP tagged TopoIIα, the supernatant was mixed with Calmodulin-Sepharose 
resin (GE Healthcare) for 90 minutes at 4°C.  The resin was then washed with 
lysis buffer, and TopoIIα was eluted with buffer containing 10 mM EGTA. For ZZ-
tagged TopoIIα, proteins were captured on IgG-Sepharose (GE Healthcare) and 
elution was performed by cleaving with  PreScission Protease (GE Healthcare) 
according to the manufacturer’s protocol. The elution was further purified by 
Mono Q anion-exchange chromatography (GE Healthcare).  The E1 complex 
(Aos1/Uba2 heterodimer), PIASy, Ubc9, dominant negative form of Ubc9 
(dnUbc9), and SUMO paralogues were expressed in BL21(DE3) or Rosetta(DE3) 
bacteria and purified as previously described.  
Anti-TopoIIα/β monoclonal antibody was purchased from MBL.  Anti-SUMO2/3 
polyclonal antibody was generated in guinea pigs, (71)and polyclonal antibody 
against TopoIIα, C-terminus (aa 1358-1579) was prepared in rabbits by injection 
with a recombinant His-T7 fused fragment, and affinity purified (8).  The anti-
PIASy antibody used in this study was reported previously (8). 
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Xenopus egg extracts, Immunodepletion-addback assays. Sperm nuclei and 
low-speed extracts of X. laevis eggs arrested in metaphase by cytostatic factor 
(CSF) were prepared following standard protocols (63,107) . Immunodepletion 
was performed as previously reported with protein A–conjugated magnetic beads 
(Dynal) (108). For addback experiments, the purified recombinant TopoIIα pro-
teins were added to the immunodepleted extracts at a final concentration of ~300 
nM, which is comparable to the concentration of endogenous TopoIIα measured 
by quantitative Western blotting. Chromosome isolation and analysis of SUMOy-
lation were performed as previously described (107).  
 
Immunofluorescence. The mitotic chromosomes for immunofluorescence 
analysis were prepared as previously described (108). Briefly, CSF extracts were 
driven into interphase by 0.6 mM CaCl2. 500 sperm/µl were incubated with the 
interphase extracts for ~60 minutes at 23°C to allow complete DNA replication. 
Then, a volume of fresh CSF extract equal to half of the original volume was 
added to induce mitosis. For inhibition of mitotic SUMOylation, a dominant nega-
tive form of Ubc9 (dnUbc9) was added just before induction of mitosis, at a final 
concentration of 150 ng/µl. After a 30 minute incubation, the reactions were di-
luted three fold and fixed with paraformaldehyde (PFA) at a final concentration of 
2%. The samples were spun onto cover slips through a 35% glycerol cushion, 
post-fixed in 1.6% PFA, and analyzed by immunostaining using antibodies 
against TopoIIα (either mouse monoclonal or rabbit polyclonal), SUMO2/3 
 76 
(guinea pig polyclonal), PIASy (rabbit polyclonal), and Aurora B (rabbit poly-
clonal). Anti-rabbit Alexa 568, anti-guinea pig Alexa 684, and anti-mouse Alexa 
488 were used as secondary antibodies. Specimens were observed using  Vo-
locity Imaging Software (Improvision) on a Nikon TE2000-U microscope with 
Plan Apo 100x/1.40 objective, and images were taken with a Retiga SRV CCD 
camera (QImaging).  
 
Purification of SUMOylated TopoIIα from mitotic chromosomes. After mitotic 
chromosomes were assembled and isolated from CSF extracts, chromosomal 
proteins were subsequently extracted by boiling the chromosome fractions with 
SDS-PAGE sample buffer. Immunoprecipitation was performed on extracted de-
natured proteins as described (83) using affinity-purified anti-TopoIIα antibody 
that had been covalently cross-linked to Protein-A Dynabeads (Invitrogen) by 
Dimethyl pimelimidate 2 HCl (Pierce Chemical Co.). Isolated proteins were sepa-
rated on 8-16% Tris-HCl gradient gels (Invitrogen) by SDS-PAGE, and visualized 
by silver staining (Owl kit, Daiichi). For LS-MS/MS analysis, the isolated proteins 
were stained with CBB-R250.  
 
In Vitro SUMOylation assays. SUMOylation reactions were incubated at 25°C 
for 1 hour unless otherwise indicated. SUMO2 was used in most of reactions ex-
cept where noted. The reactions contained 15 nM E1, 5 µM SUMO2-GG, 500 nM 
T7-tagged TopoIIα, 2.5 mM ATP, and various concentrations of Ubc9 and PIASy 
as indicated in Fig. 5. Reaction buffers were composed of 20 mM HEPES (pH 
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7.8), 100 mM NaCl, 5 mM MgCl2, 0.05% Tween20, 5% glycerol, 1mM AEBSF 
and 1 mM DTT. The reactions were stopped with half volumes of 3× SDS-PAGE 
sample buffer, and the samples were resolved on 8-16% Tris-HCl gradient gels 
by SDS-PAGE, and analyzed by Western blot with HRP conjugated anti-T7 
monoclonal antibody (EMD Biosciences).  
 
In vitro SUMOylation-Decatenation coupled assays. These assays were per-
formed with 60 nM Ubc9 and 30 nM PIASy together with other protein compo-
nents as described above. A control was performed under the same conditions 
except that SUMO2-G was used instead of SUMO2-GG. After 1 hour incubation 
at 25°C, the non-SUMOylated (Cont.) and SUMOylated samples were further in-
cubated with 6.2 ng/ul of kDNA (TopoGEN, Inc.) in decatenation buffer at 25°C 
for the indicated time periods. Decatenation buffer consisted of 50 mM Tris-HCl 
(pH 8.0), 120 mM NaCl, 5 mM MgCl2, 0.5 mM DTT, 30 µg BSA/ml, and 2 mM 
ATP. The reactions were stopped by adding one third volume of 6X DNA dye 
(30% glycerol, 0.1% SDS, 10 mM EDTA, and 0.2 µg/ul bromophenol blue), and 
samples were loaded on a 1% agarose gel and electrophoresed at 100V in TAE 
buffer until the samples reached the middle of the gel.  The amount of kDNA re-
maining in the wells was measured using an Image Station 4000R (Kodak) and 
standard error was calculated using Kaleidagraph (Synergy Software).  
 
Electrophoretic Mobility Shift Assay. The assay was performed as described 
previously (109) with slight modifications. In brief, various amounts of TopoIIα 
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WT and K660R (as indicated in Figure 5b) were incubated with 90ng of pBS 
KS(+) DNA for 5 min at 25°C. In vitro SUMOylation reaction buffer was used as 
the reaction buffer in these assays in order to keep protein-DNA binding condi-
tions similar to those used in in vitro SUMOylation reactions. The reactions were 
stop by adding one half volume of loading buffer (50% glycerol, 10mM EDTA, 
and 0.2% Bromophenol Blue) and the samples were subjected to electrophoresis 
at 40V for 2 hours at 4°C in a 1% agarose gel containing ethidium bromide. The 
DNA was documented using an Image Station 4000R.  
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Results 
 
PIASy promotes SUMO2/3 conjugation of TopoIIα in Xenopus egg extracts.  
We previously demonstrated using a Xenopus Egg Extract (XEE) cell-free 
assay, that TopoIIα is modified by SUMO2/3 in a PIASy-dependent manner (8). 
More recently, studies in MEFs suggested that RanBP2 promotes SUMOylation 
of TopoIIα through SUMO1 conjugation (106).  To investigate whether RanBP2 
has a role in SUMOylation of TopoIIα in XEE assays, we immunodepleted XEE 
of specific E3 enzymes (RanBP2, PIASy, or RanBP2/PIASy) and examined 
TopoIIα for alterations in SUMOylation.  Following immunodepletion of RanBP2 
from XEE, SUMO2/3 modification was still intact in the chromosomal fractions 
(indicated by the bracket in Fig. 3.1a). In contrast, no detectable TopoIIα SU-
MOylation was observed in the absence of PIASy (Fig. 3.1a).  The lack of 
SUMO1-modified proteins associated with mitotic chromosomes indicates that 
TopoIIα on mitotic chromosomes is exclusively modified by SUMO2/3 (Fig. 3.1a). 
We further analyzed PIASy-dependent SUMO2/3 modification of TopoIIα on 
mitotic chromosomes by immunofluorescence microscopy. Using EGFP-fused 
SUMO2 in XEE assays, we previously showed that SUMO2/3-modified proteins 
are localized on inner centromeric regions (8).  For the current study, we pre-
pared an antibody to enable visualization of endogenous SUMO2/3 on chromo-
somes. Mitotic chromosomes prepared from replicated chromatin in XEE were 
fixed and immunostained using antibodies specific for TopoIIα, PIASy, and 
SUMO2/3 (Fig. 3.1b). We observed that PIASy localizes to distinct foci on mitotic 
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chromosomes and these foci overlap with SUMO2/3 localization (Fig. 3.1b). Be-
cause endogenous SUMO2/3 also co-localizes with an inner centromeric marker, 
Aurora B (Figure 3.2), we conclude that PIASy displays centromeric localization.  
Finally, we verified the localization of TopoIIα using two different antibodies.  
Both antibodies revealed that TopoIIα is located throughout the chromosome 
axis with clear accumulation at the centromeres of mitotic chromosomes as pre-
viously shown in other species (Fig. 3.1b and 3.2) (96,110).  Overall, the co-
localization of TopoIIα and SUMO2/3 was clearly apparent at the centromeric re-
gions, but not in other parts of the chromosome, suggesting that SUMOylation of 
TopoIIα mainly occurs at the centromere and in proximity to PIASy (Fig. 3.1b).  
The staining pattern of TopoIIα did not change following addition of dominant 
negative Ubc9, (dnUbc9), which prevents SUMOylation, indicating that localiza-
tion of TopoIIα was not altered by the perturbation of SUMOylation (Fig. 3.1b and 
3.2). Since we found no evidence for RanBP2 involvement in SUMO2/3 modifica-
tion of TopoIIα in our assay system, we focused our subsequent studies on PI-
ASy-mediated TopoIIα SUMOylation. 
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Figure 3. 1 
PIASy but not RanBP2 is required for SUMO2/3 conjugation of TopoIIα in XEE. 
(a) XEE were immunodepleted using antibodies against RanBP2, PIASy, or 
RanBP2/PIASy. The depleted extracts were incubated with 10,000 sperm nu-
clei/µl for 1 hour at 25°C. Non- or mock (IgG)-depleted extracts were also sub-
jected to the same procedure. Isolated chromosomes from each reaction were 
analyzed by Western blot (WB) for the indicated protein. Immunodepletion (ID) of 
RanBP2 had no effect on the SUMOylation of TopoIIα whereas PIASy ID elimi-
nated TopoIIα SUMOylation. (b) The mitotic chromosomes were prepared as in 
METHODS and were analyzed by immunostaining with the indicated antibodies: 
TopoIIα in red, PIASy in green, and SUMO2/3 in blue in merged panel. TopoIIα 
co-localized with PIASy and SUMO2/3 at the centromeres. Addition of dnUbc9 
eliminated SUMO2/3 modification but did not alter the localization of TopoIIα at 
the centromeres of mitotic chromosomes.   
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Figure 3. 2 
TopoIIα colocalizes with AuroraB on the centromere of mitotic chromosomes. 
The mitotic chromosomes were prepared as in Figure 1 and samples were ana-
lyzed by immunostaining as indicated. (Left panels) monoclonal TopoIIα (N-ter.) 
in red, AuroraB in green, and SUMO2/3 in blue in merged panel. (Right panels) 
polyclonal TopoIIα (C-ter.) in red and SUMO2/3 in green. Both monoclonal and 
polyclonal TopoIIα antibodies showed indistinguishable staining. Bars : 10µm 
 
 
PIASy promotes SUMO2/3 conjugation of TopoIIα in reconstituted in vitro 
SUMOylation assays. 
We previously demonstrated the requirement of PIASy activity for SUMOyla-
tion of chromosomal TopoIIα in XEE assays (71).  However, due to the extreme 
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instability of the SUMOylation reaction, experimentally managing the state of 
SUMOylation in vivo was difficult, limiting the use of XEE assays for further in-
vestigations of TopoIIα SUMOylation. Therefore, we next sought to examine the 
PIASy-dependent SUMOylation of TopoIIα in an in vitro assay.  For these stud-
ies, all of the protein components required for SUMOylation were prepared as 
described in METHODS. For most in vitro SUMOylation reactions, we used 
500nM T7-taged TopoIIα, 5uM SUMO and 15nM E1 (Aos1/Ubc2), and the SU-
MOylation was detected by western blot using the T7 tag. 
Ubc9, a SUMO E2 conjugating enzyme, directly binds to its consensus se-
quence on substrates without E3 ligase (64,88) and, in fact, major SUMOylation 
sites of budding yeast TopoII were identified based on this consensus sequence 
(102).  Hence, we sought to identify whether SUMOylation of Xenopus TopoIIα is 
dependent on Ubc9. Purified Xenopus TopoIIα was incubated with various con-
centrations of Ubc9 and analyzed by western blot.  Our results indicated that 
Ubc9 could promote SUMOylation of TopoIIα in a dose-dependent manner (Fig. 
3.3a) and 300 nM Ubc9 was sufficient to promote SUMOylation of more than 
50% of the TopoIIα. However, when the concentration of Ubc9 was close to the 
endogenous levels found in XEE, 30nM, the efficiency of TopoIIα SUMOylation 
dropped to barely detectable levels (Fig. 3.3a, b).   
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Figure 3. 3 
PIASy is required for the efficient SUMOylation of TopoIIα and for the selection of 
SUMO paralogues. (a) Ubc9 dosage dependent SUMOylation. T7 tagged-
TopoIIα was incubated in a reaction containing various concentrations of Ubc9 
(0-300nM) in the presence of SUMO2. The amount of SUMO2-conjugated 
TopoIIα was similar to that seen in XEE only when 300nM Ubc9 was added. (b) 
Time course experiment with physiological (30nM) and higher (300nM) concen-
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tration of Ubc9. (c) PIASy dosage-dependent SUMOylation. T7-TopoIIα was in-
cubated as in (a) except with various concentrations of PIASy (0-100nM) and 
with the physiological concentration of Ubc9 (30nM). PIASy efficiently facilitated 
SUMOylation of TopoIIα under conditions using 30nM Ubc9, where SUMOylation 
had barely appeared in the absence of PIASy. SUMOylation was saturated using 
more than 60nM PIASy. (d) Time course experiment of PIASy-dependent SU-
MOylation. The reactions were performed with physiological (10nM) or higher 
(100nM) concentrations of PIASy in the presence of 30nM Ubc9. (e) T7-TopoIIα 
was incubated with either SUMO1 (s1) or SUMO2 (s2) in the presence of PIASy 
as indicated. PIASy showed a preference for SUMO2 over SUMO1.  
 
Next, to assess the contribution of PIASy to SUMOylation, TopoIIα was in-
cubated with various concentrations of PIASy using a physiologically relevant 
concentration of Ubc9 (30nM). Under such conditions, TopoIIα was efficiently 
SUMOylated in the presence of PIASy and could be SUMOylated even when PI-
ASy concentration was 10nM, which is near the endogenous level in XEE (Fig. 
3.3c, d).  
The observation that TopoIIα is specifically modified by SUMO2/3 in XEE led 
us to hypothesize that PIASy may select the SUMO paralogue for the conjuga-
tion.  To test this hypothesis, TopoIIα was incubated with either SUMO1 or 
SUMO2 in the presence of PIASy and physiological concentrations of Ubc9. This 
assay revealed that PIASy mediates modification of TopoIIα by SUMO2 but not 
by SUMO1 (Fig. 3.3e), even though SUMO1 was highly active with RanGAP1 as 
the substrate (data not shown) as previously shown (82). This indicates that PI-
ASy plays a role in the selection of SUMO paralogues.  We also confirmed that 
PIASy mediates modification of TopoIIα with SUMO3 in similar level to with 
SUMO2 (data not shown). Together, we conclude that PIASy is an essential 
element for SUMO2/3 modification of TopoIIα under physiological conditions. 
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PIASy-mediated SUMOylation inhibits the decatenation activity of TopoIIα.  
Previous studies in HeLa cells have suggested that PIASy is required for 
regulation of cohesin-independent cohesion of centromeres (73).  We speculated 
that PIASy might play a role in localizing TopoIIα to the centromere by regulating 
its SUMOylation; however, we found that inhibition of SUMOylation did not alter 
TopoIIα localization in XEE assays (Fig. 3.1b).  Therefore, we examined whether 
PIASy-dependent SUMOylation alters TopoIIα activity, which is required for 
proper chromosome segregation. To this end, TopoIIα was incubated in an in vi-
tro SUMOylation reaction with either processed form of SUMO2 (SUMO2-GG), or 
a truncated form of SUMO2 (SUMO2-G) that cannot be conjugated to substrates 
due to a lack of one C-terminal glycine. SUMOylated and non-SUMOylated 
TopoIIα were then analyzed for decatenation activity using kinetoplast DNA 
(kDNA) as substrate. Once decatenated by TopoIIα, the interlocking chain of cir-
cular kDNA releases to form minicircles. As shown in Figure 3.4a, TopoIIα was 
differentially SUMOylated in 60 min in vitro using various concentrations of Ubc9 
and PIASy in the presence of SUMO2-GG.  A control reaction that contained 
Ubc9 and PIASy in the presence of SUMO2-G showed no SUMOylation. West-
ern blot analysis revealed that the intensity of TopoIIα SUMOylation could be 
controlled by the in vitro reaction conditions and that more than 50% of the 
TopoIIα was modified under each condition. Subsequent assays indicated that 
the decatenation activity of TopoIIα is markedly inhibited by SUMO conjugation 
(Fig. 3.4b, c). One interesting aspect of this analysis is that, despite subtle differ-
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ences in TopoIIα SUMOylation among the series of reactions, the presence of 
the highest molecular weight band (indicated by the arrow in Fig. 3.4a) appeared 
to correlate with strong inhibition of TopoIIα decatenation activity. Together, our 
results indicate that PIASy-mediated SUMO modification of TopoIIα inhibits 
TopoIIα decatenation activity.  
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Figure 3. 4 
SUMO modification affects the decatenation activity of TopoIIα. (a) T7-
TopoIIα was incubated with various combinations of Ubc9/PIASy as indicated to 
obtain a series of SUMOylation profiles. All control reactions (Cont.) were per-
formed with 60nM Ubc9/10nM PIASy and SUMO2-G which could not be conju-
gated. The samples were analyzed by Western blot for T7 tag. Arrow indicates 
maximal SUMO modification of TopoIIα (seen in 30/30 and 60/10). (b) Represen-
tative data of decatenation assay. Samples in (a) were further incubated with de-
catenation buffer that contained kinetoplast DNA (kDNA) for 10 or 20 minutes 
and the products were resolved in an agarose gel. Decatenated and linearized 
markers are designated. (c) Band intensity data from five independent experi-
ments performed as in b are presented as % catenated kDNA remaining after 20 
min incubation with standard error and probability value from Student-t test. 
SUMO2 modification of TopoIIα decreased its decatenation activity.  
 
Lysine at 660 is one SUMOylation site of TopoIIα in XEE. 
To better understand the molecular basis of TopoIIα inhibition by SUMOyla-
tion, we sought to identify SUMOylation sites of TopoIIα. To this end, a SUMOy-
lated form of endogenous TopoIIα was purified from mitotic chromosomes pre-
pared in XEE (Figure 3.5). Isolated bands were double-digested with trypsin and 
chymotrypsin followed by mass spectrometric analysis using the same method 
as used to identify the SUMOylation site of poly (ADP-ribose) polymerase I 
(PARP1), another mitotic chromosomal substrate (10). Double digestion with 
trypsin and chymotrypsin generates a remnant of the SUMO sequence 
(QQQTGG, with a mass of 599.2663 Da) on the lysine of a SUMO modified pep-
tide. With approximately 50% sequence coverage, lysine residue 660 (Lys660, 
K*EWLTNFMQDR, where * refers to QQQTGG) was shown to have the SUMO 
signature in the digested pool of SUMO2/3-TopoIIα (Figure 3.6).  This result was 
unexpected given that 1) the sequences surrounding Lys660 do not match the 
canonical or non-canonical consensus sequences predicted using a SUMO pre-
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diction program (111), and 2) the genetically determined SUMOylation sites in 
budding yeast were all located in the C-terminal domain (28,102) while Lys660 is 
located in the core active domain (DNA-gate) of TopoIIα (32,112) (Fig. 3.7a).  
Also, it was striking that the sequences including and surrounding Lys660 are 
highly conserved, from yeast to human (Fig. 3.7a).  
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Figure 3. 5 
Isolation of SUMOylated TopoIIα for mapping SUMOylation site(s) by Mass spec-
trometry. Chromosomal proteins were isolated from mitotic chromosomes that 
were assembled in CSF extracts (Cont.), CSF extracts with exogenous PIASy 
(+PIASy) or dnUbc9 (+dnUbc9) using SDS-PAGE sample buffer. After samples 
were renatured with buffer containing thesit, the extracted fractions were im-
munoprecipitated with affinity purified anti-TopoIIα antibody. Immuno-precipitated 
fractions were further separated by SDS-PAGE and silver stained (Owl/Daiichi). 
Both SUMOylated (bracket) and non-SUMOylated TopoIIα (arrow head) were 
subjected to MS/MS analysis: in brief, the samples were double digested with 
trypsin and chymotrypsin. The Chymotrypsin digestion provides the QQQTGG 
signature tag on the modified lysine. The MS/MS analysis, with around 50% 
TopoIIα sequence coverage, indicated lysine 660 as a candidate site for SUMOy-
lation (detailed LC-MS/MS analysis data is shown in Figure 3.6).  
 
 
 
 
 
Figure 3. 6 
SUMOylation of TopoIIα at K660 was identified by LC-MS/MS following tryp-
sin/chymotrypsin double digest.  a-b) Precursor of 695.33 m/z was isolated and 
fragmented, with a series of b- and y- ions matching the sequence 
K#EWLTNFM*QDR.  Asterisk refers to oxidized methionine.  The SUMO2/3 sig-
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nature of QQQTGG is denoted by #.  The measured m/z of the monoisotopic 
precursor ion (694.9938) matched the expected within 0.3 ppm. c) Multiple ion 
species, denoted by interlaced isotopic envelopes (blue, green) were found co-
eluting within the isolation window of the SUMOylated TopoIIα peptide (red).   
 
 
 
 
 
Figure 3. 7 
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 TopoIIα K660R, a candidate SUMOylation mutant, shows incomplete SUMOyla-
tion in XEE. (a) Schematic diagram of S. cerevisiae TopoIIα primary structure. 
Domains are denoted by color. (Modified from (99)).   TOPRIM: Topoisomerase-
primase fold domain, WHD: Winged-helix domain, Tower: Adjacent domain to 
WHD, black bar indicates the catalytic tyrosine (Y782) for DNA cleavage in the 
WHD domain.  Lys660 in X. laevis TopoIIα was designated as a potential SU-
MOylation site by mass spectrometric analysis. The approximate position of the 
candidate lysine is shown by a green star in the DNA-gate domain of TopoIIα. 
The sequences near TopoIIα Lys660 from X. laevis (xl), homo sapiens (hs), and 
S. cerevisiae (sc) are conserved. (b) XEE were immunodepleted using non-
specific IgG (Cont.) or an anti-TopoIIα antibody (-Topo). Efficiency of TopoIIα 
depletion was confirmed by comparison of mock-depleted (Cont.) to TopoIIα-
depleted (-Topo) CSF extracts (left two lanes, labeled CSF extracts). Wild type 
non-tagged TopoIIα (WT) or mutant TopoIIα, with substitution of arginine for 
Lys660 (K660R) was added to the TopoIIα-depleted extracts (-Topo). After 1hour 
incubation at 25°C, mitotic chromosomes were isolated and analyzed by anti-
TopoIIα Western blot. Analyzed chromosome samples were from mock-depleted 
(Cont.), TopoII-depleted (-Topo) and recombinant TopoIIα added-back extracts (-
Topo+WT or –Topo+K660R). (c) Same examination as in (b) except that the re-
combinant TopoIIα proteins had a T7-tag at the N-terminus. Both non-tagged and 
T7-tagged K660R mutant showed subtle but reproducible reduction in higher 
shifted bands (indicated by bracket) of SUMOylation compared to WT. 
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Figure 3. 8 
The purity of TopoIIα WT and K660R proteins. Recombinant proteins of TopoIIα 
was expressed and purified as described in METHODS, and 200ng of each pro-
tein was resolved on a 8-16% gradient gel and coomassie blue stained to deter-
mine purity of the proteins. WT and K660R show comparable quality. 
 
 
To confirm the mapping result, recombinant wild type TopoIIα (WT) or 
TopoIIα with an arginine substitution for Lys660 (K660R) were prepared as de-
scribed in METHODS, and the purity of these recombinant proteins was con-
firmed, as shown in Figure 3.8.  Add-back experiments of the recombinant pro-
teins to TopoIIα -immunodepleted XEE indicated that the K660R mutant exhib-
ited a slight reduction in higher shifted species of SUMOylated TopoIIα compared 
to that of WT. Although major SUMOylations still occurred (Fig. 3.7b and c), us-
ing both an untagged (Fig. 3.7b) and T7-tagged (Fig. 3.7c) recombinant TopoIIα, 
K660R showed a reproducible deficiency in generating SUMOylation represented 
by higher shifted bands. In summary, Lys660 is a SUMOylation site of TopoIIα 
associated with mitotic chromosomes in XEE, and other SUMOylation sites re-
main to be identified. 
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Figure 3. 9 
The elimination of TopoIIα SUMOylation at Lys660 blocks SUMOylation-
dependent inhibition of TopoIIα activity. (a) unmodified TopoIIα WT and K660R 
proteins were incubated with kDNA to determine relative activity. K660R had ap-
proximately 20 times less activity than WT. (b) Electrophoretic mobility shift as-
say. Unmodified TopoIIα WT and K660R were incubated with plasmid DNA to 
determine relative DNA binding affinity. Both WT and K660R displayed similar 
binding affinity to DNA. Oc and cc stand for open and closed circle, repectively. 
(c, e) The TopoIIα WT and K660R were SUMO2-modified in vitro with 60nM of 
Ubc9 and 30nM of PIASy. Control reactions (Cont.) using the same condition ex-
cept for SUMO2-G were also performed. Non- or SUMOylated TopoIIα samples 
were assayed for decatenation activity. (d, f). Representative results of decate-
nation activity assays with TopoIIα WT (c) and K660R (f) are shown. The aver-
age decatenation activity from five independent experiments with TopoIIα WT (g) 
and four independent experiments with TopoIIα K660R (h) are displayed as % 
catenated kDNA remaining, with standard error. The strong inhibition of TopoIIα 
decatenation activity by SUMOylation was abolished in reactions using TopoIIα 
K660R.  
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Lack of TopoIIα SUMOylation at Lys660 abolishes SUMOylation-dependent 
inhibition of TopoIIα activity.  
Available X-ray crystal structure information for TopoIIα indicates that 
Lys660 faces DNA (113). Therefore, we predicted that alteration of Lys660 would 
affect TopoIIα activity. Indeed, when we compared the decatenation activity of 
recombinant, unSUMOylated WT and K660R TopoIIα, K660R was approximately 
20 times less active than WT (Fig. 3.9a). Yet, gel mobility shift assays showed 
that both WT and K660R bind to DNA with similar affinity (Fig. 3.9b), suggesting 
lower decatenation activity of K660R is not simply due to the deficiency of DNA 
binding. Given that the relatively minor alteration, substituting Lys660 with argin-
ine, reduces TopoIIα decatenation activity, we speculated that SUMO conjuga-
tion of Lys660 might have a significant impact on the activity of TopoIIα.  
To test this, TopoIIα WT and K660R were applied to the in vitro SUMOyla-
tion-decatenation coupled assay. For SUMOylation reactions (Fig. 3.9c, e), we 
used 60/30 nM of Ubc9/PIASy to better observe the inhibition of TopoIIα WT de-
catenation activity by SUMOylation and the potential alteration in the SUMOyla-
tion-dependent regulation of TopoIIα activity for the K660R mutant. Consistent 
with our earlier results, the decatenation activity of TopoIIα WT was efficiently 
inhibited by SUMO modification (Fig. 3.9d, g). On the other hand, it was striking 
that the decatenation activity of TopoIIα K660R was no longer inhibited by SUMO 
modification (Fig. 3.9f, h) despite the fact that both TopoIIα WT (Fig. 3.9c) and 
K660R mutant (Fig. 3.9e) were robustly modified by SUMO2. Similar results were 
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obtained using different tagged TopoIIα WT and K660R for the analysis (Figure 
3.10). These results suggest that PIASy-mediated SUMOylation on Lys660 have 
a crucial role in the regulation of TopoIIα activity.  
 
Figure 3. 10 
The elimination of the SUMOylation at K660 abolishes the SUMOylation-
mediated inhibition of TopoIIα activity. TopoIIα proteins that were fused to T7-tag 
and ZZ-tag at the N- and C-terminus, respectively, were purified by ZZ-affinity 
using IgG sepharose column (GE healthcare). The ZZ-tag was removed by Pre-
Scission protease (GE healthcare). Further purified T7-TopoIIα was applied to 
the SUMOylation-decatenation coupled assay as in Figure 5. (a) Representative 
result of SUMOylation-decatenation coupled assay with TopoIIα WT. (b) Repre-
sentative result of SUMOylation-decatenation coupled assay with 
TopoIIα K660R. (c) Representative samples of in vitro SUMOylated TopoIIα WT 
and K660R. In vitro samples were analyzed by western blot for T7 tag. Control 
(Cont.) contained SUMO2-G instead of SUMO2-GG. (d, e) Results from four in-
dependent experiments performed as in a are presented as average of % cate-
nated DNA remaining with standard error. The different preparations of TopoIIα 
showed the same results as in Fig. 3.9.  
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SUMOylation of TopoIIα Lys660 is regulated by DNA. 
Based on X-ray crystalographic structure analysis, TopoIIα Lys660 lies near 
the DNA backbone and appears not easily accessible for SUMOylation (113). We 
speculated that this limited accessibility might correlate with our inability to see a 
dramatic difference in the in vitro SUMOylation profile of WT and K660R TopoIIα, 
even though we observed subtle but reproducible reduction of K660R TopoIIα 
SUMOylation in XEE assays (Fig. 3.7b,c). We suspected that when TopoIIα 
binds to DNA it changes conformation, making it susceptible to SUMOylation of 
Lys660 in the XEE assay. To examine this hypothesis, we performed in vitro 
SUMOylation assays with WT TopoIIα in the presence or absence of DNA. As 
shown in Figure 3.11a, WT TopoIIα was extremely susceptible to SUMOylation in 
the presence of DNA. Addition of DNA to the in vitro reaction increased the 
amount of TopoIIα SUMOylation as well as the rate of modification, such that the 
amount of SUMOylated WT TopoIIα after one hour incubation without DNA was 
comparable to that formed after 10 minutes with DNA (Fig. 3.11a).  
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Figure 3. 11 
DNA binding of TopoIIα increases susceptibility of SUMOylation at Lys660. (a) 
TopoIIα WT in vitro SUMOylation reactions were performed with or without DNA. 
The samples were analyzed with anti-T7 tag antibody Western blots. The pres-
ence of DNA in the SUMOylation reactions significantly stimulates TopoIIα WT 
SUMOylation. (b) TopoIIα WT and TopoIIα K660R were subjected to in vitro re-
actions under the same condition as in (a) except for using 5ng/µl of DNA. 
PARP1, a mitotic chromosomal SUMO2/3 substrate, was used as control. A defi-
ciency of TopoIIα K660R SUMOylation is observed in the presence of DNA com-
pared to TopoIIα WT.  
 
Since both TopoIIα and PIASy can bind DNA, we also considered the possi-
bility that DNA acts as an adaptor to increase the binding affinity of TopoIIα and 
PIASy, leading to acceleration of SUMOylation.  However, because the SUMOy-
lation of PARP1, another chromosomal substrate of SUMO2/3 found in XEE (10), 
is barely affected by the addition of an equivalent amount of DNA (Fig. 3.11b), 
this possibility seems unlikely, supporting the idea that DNA-dependent en-
hancement of TopoIIα SUMOylation results from exposure of a SUMOylation 
site(s) by DNA binding. Remarkably, we found that the K660R mutant displayed 
a reduction of SUMOylation in the presence of DNA, albeit there was no signifi-
cant difference in the SUMOylation profile between WT and K660R in the ab-
sence of DNA (Fig. 3.11b). Considering the comparable DNA binding affinity of 
both proteins (Fig. 3.9b), therefore, it is reasonable to conclude that the alteration 
of TopoIIα conformation by DNA binding (32,113,114) increases the efficiency of 
TopoIIα SUMOylation. Together, our results suggest that there is a SUMOylation 
site(s) of TopoIIα whose availability for SUMOylation depends on the conforma-
tional change of TopoIIα resulting from DNA binding and that the SUMOylation of 
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Lys660, which plays a key role in SUMOylation-dependent TopoIIα inhibition, is 
one of those sites.  
 
Figure 3. 12 
Implications of SUMOylation in regulating the resolution of centromeric DNA.  (a) 
Regulating amount of catenated centromeric DNA.  Active TopoIIα resolves 
catenated DNA at the centromere and SUMOylation reduces the activity of 
TopoIIα which has completed the decatenation of DNA. Without SUMOylation, 
overly active TopoIIα could recatenate DNA at the centromere. (b) Regulation of 
timing of decatenation. TopoIIα SUMOylation keeps centromeric TopoIIα tempo-
rally inert until anaphase, when decatenation of centromeric DNA must take 
place. Without proper deSUMOylation of TopoIIα, decatenation of centromeric 
DNA will be compromised. 
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Discussion 
 
The central achievement of this paper is finding the SUMOylation-dependent 
regulation of TopoIIα activity. We previously reported that SUMOylation of 
TopoIIα did not significantly alter its enzymatic activity when using TopoIIα-
containing fractions from XEE (71). However, we anticipated a potential role for 
SUMOylation in the regulation of TopoIIα activity, based on the difficulty separat-
ing SUMOylated TopoIIα associated with centromeres from unSUMOylated 
TopoIIα associated with other chromosome regions. The in vitro SUMOylation 
assay established for the current study allowed us to overcome the time and 
space obstacles of SUMOylation of TopoIIα, and thus to reexamine the possible 
role of SUMOylation in regulating TopoIIα activity during mitosis. Our assay 
clearly reveals that SUMOylation significantly inhibits the decatenation activity of 
TopoIIα and that this inhibition is correlated with the TopoIIα SUMOylation pro-
file. That is, the existence of the highest shifted species of SUMOylated TopoIIα, 
which appear when relatively high concentration of enzymes (Fig. 3.4a) or DNA 
are added to the reactions (Fig. 3.11a), correlates with strong inhibition of 
TopoIIα activity.  
The identification of Lys660 as a SUMOylation site further supports the prem-
ise that TopoIIα activity is SUMOylation dependent. Lys660 is located within the 
DNA-gate, which plays a key role in manipulation of double helical DNA strands 
(99,113). Considering the importance of this region for TopoIIα function, it was 
predictable that even slight alteration of Lys660 would impact the activity of 
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TopoIIα. Supporting this idea, replacement of Lys660 with arginine resulted in a 
substantial reduction of the TopoIIα decatenation activity (Fig. 3.9a), although no 
loss of DNA binding is observed (Fig. 3.9b). Notably, the abolition of SUMO 
modification at Lys660 eliminated the SUMOylation-dependent inhibition of 
TopoIIα decatenation activity. The interpretation of this result is obviously limited 
by the lower catalytic activity of the Lys660 mutant, which might render partial 
inhibition due to SUMOylation of other sites of TopoIIα imperceptible. Therefore, 
detailed kinetic analyses of TopoIIα reactions, combined with analysis of other 
currently unidentified SUMOylation site(s) will be necessary to clarify the function 
of each TopoIIα SUMOylation site. 
We further observed that Lys660 SUMOylation is enhanced in the presence 
of DNA, and this is likely due to exposure of the Lys660 site during the catalytic 
action of TopoIIα (Fig. 3.11b). The hypothesis that an active TopoIIα conforma-
tion makes Lys660 more susceptible to SUMOylation is supported by an earlier 
report that etoposide (or VP16) treatment of human cells induces hyperSUMOy-
lation of TopoIIα at the centromere (115). Etoposide immobilizes TopoIIα in an 
intermediate structure with cleaved DNA (116), thus potentially exposing a SU-
MOylation site(s) as shown in Figure 11. Taken together, our results strongly 
suggest that SUMOylation of Lys660 is responsible for the control of decatena-
tion activity. However, it is possible that other TopoIIα SUMOylation sites con-
tribute to changes in TopoIIα activity.  
The IR-domain of RanBP2 possesses SUMO E3 ligase activity in vitro, and 
studies in RanBP2-deficient mouse embryonic fibroblasts (MEFs) have impli-
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cated RanBP2 in SUMO1 conjugation of TopoIIα (106). We found that the IR-
domain of RanBP2 could enhance TopoIIα SUMOylation in vitro (data not 
shown), but paralogue specificity and SUMOylation site selection under these 
conditions were different from TopoIIα SUMOylation in XEEs. There are a num-
ber of other findings that argue against a role of RanBP2 as the primary E3 en-
zyme for TopoIIα in mitosis: First, the addition of Nocodazole, which disrupts the 
localization of RanBP2 from the centromere (117), does not eliminate SUMOyla-
tion of TopoIIα (107). Second, while Dawlaty et al. (2008) found that RanBP2 
promotes SUMO1 conjugation of TopoIIα, TopoIIα is exclusively conjugated to 
SUMO2/3 in XEEs unless ectopic SUMO1 is supplied (71). Finally, we observed 
that SUMO2/3 modification of TopoIIα on mitotic chromosomes was intact in 
RanBP2-immunodepleted XEEs unless PIASy was co-depleted (Fig. 3.1a), 
strongly suggesting that RanBP2 is dispensable. Additionally, endogenous 
TopoIIα, PIASy and SUMO2/3 co-localized at the centromeres of mitotic chromo-
somes (Fig. 3.1b), consistent with the notion that PIASy is the E3 enzyme for 
TopoIIα SUMOylation at this site. By contrast, RanBP2 localizes to the outer ki-
netochore (117). It is possible that the discrepancy between findings in XEEs and 
MEFs simply reflects the difference in experimental systems, and that different 
SUMO ligases mediate TopoIIα conjugation in mice and frogs. Alternatively, we 
have recently shown that centromeric SUMOylation results from precise localiza-
tion of PIASy and its substrates (118). RanBP2 might indirectly affect the SU-
MOylation of TopoIIα by regulating the localization of TopoIIα centromeres in 
MEFs through a mechanism that is not used in XEEs. The failure to localize 
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TopoIIα could thus impair its subsequent PIASy-dependent SUMO2/3 modifica-
tion.  
Our findings that 1) PIASy colocalizes with TopoIIα at the centromere where 
enzymatically active TopoIIα is thought to accumulate (33), 2) the DNA-bound 
form of TopoIIα is more susceptible to SUMOylation on Lys660, and 3) the SU-
MOylation of Lys660 inhibits TopoIIα activity, lead us to propose that PIASy-
dependent SUMOylation of TopoIIα regulates centromeric catenation. In this 
model, when SUMOylation is depressed, overly active TopoIIα leads to DNA re-
catenation at the centromeres where sister chromatids are highly compact and 
close to each other. With proper SUMOylation, active TopoIIα is rendered tempo-
rarily inert to prevent re-catenation (Fig. 3.12a), and so only the proper amount of 
catenated DNA remains avoiding early disjunction of sister chromatid before 
anaphase. This model explains why the perturbation of SUMOylation by either 
the elimination of PIASy or addition of dnUbc9 causes abnormal chromosomal 
segregation as represented by anaphase bridges, which could be the result of 
hypercatenation of centromeric DNA (8,71). The model also explain why deple-
tion of PIASy in HeLa cells produces cohesin-independent sister chromatids co-
hesion (73).  
There are several pieces of evidence that support a requirement of TopoIIα 
activity for proper anaphase execution. According to a recent study of PICH-
positive (Plk1-interacting checkpoint helicase) DNA threads, centromeric DNA 
catenation was resolved at the onset of anaphase (119). Wang et al. also dem-
onstrated that TopoIIα decatenates centromeric DNA after removal of the cohe-
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sin complex (98). Lastly, TopoIIα SUMOylation is highly dynamic, with TopoIIα 
heavily modified by SUMO during metaphase and the rapid disappearance of 
modified TopoIIα at the onset of anaphase (71). In this context, it is possible that 
deSUMOylation of TopoIIα regulates the timing of resolution of the catenated 
DNA at the centromere at the onset of anaphase. At anaphase, when the cen-
tromeres of sister chromatids are distal enough, deSUMOyation of TopoIIα al-
lows the preferential decatenation of the last tangled sister chromatids. As such, 
we further propose that deSUMOylation of TopoIIα is critical to control the timing 
of the final decatenation at anaphase (Fig. 3.12b). Extensive analysis using spe-
cific deSUMOylation enzymes of TopoIIα must be performed to directly test this 
hypothesis.  
In summary, our finding that TopoIIα activity is inhibited by PIASy-mediated 
SUMOylation allows us to answer a long-standing question of how the catalytic 
activity of TopoIIα is tightly regulated in a space- and time-dependent manner. 
Future studies using somatic cells to observe consequential phenotypes caused 
by SUMOylation-deficient TopoIIα and an examination of specific deSUMOyla-
tion mechanisms of TopoIIα will strengthen the functional significance of SUMO-
modified TopoIIα .  
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CHAPTER 4 
Rod/Zw10 complex is required for PIASy-dependent  
centromeric SUMOylation. 
 
Abstract 
SUMO conjugation of cellular proteins is essential for proper progression 
of mitosis. PIASy, a SUMO E3 ligase, is required for mitotic SUMOylation of 
chromosomal proteins, yet the regulatory mechanism behind the PIASy-
dependent SUMOylation during mitosis has not been determined. Using a series 
of truncated PIASy proteins, we have found that the N-terminus of PIASy is not 
required for SUMO modification in vitro but is essential for mitotic SUMOylation in 
Xenopus egg extracts. We demonstrate that swapping the N-terminus of PIASy 
protein with the corresponding region of other PIAS family members abolishes 
chromosomal binding and mitotic SUMOylation. We further show that the N-
terminal domain of PIASy is sufficient for centromeric localization. We identified 
that the N-terminal domain of PIASy interacts with the Rod/Zw10 complex, and 
immunofluorescence further reveals that PIASy colocalizes with Rod/Zw10 in the 
centromeric region. We show that the Rod/Zw10 complex interacts with the first 
47 residues of PIASy which were particularly important for mitotic SUMOylation. 
Finally, we show that depletion of Rod compromises the centromeric localization 
of PIASy and SUMO2/3 in mitosis. Together, we demonstrate a fundamental 
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mechanism of PIASy to localize in the centromeric region of chromosome to exe-
cute centromeric SUMOylation during mitosis.   
 
Introduction 
SUMOylation is a protein modification process conserved from yeast to 
vertebrates (5). The consequences of SUMO (small ubiquitin like modifier) modi-
fication that have been elucidated over the past decade include modulation of 
gene transcription, DNA repair, protein translocation, protein/protein interaction, 
chromosomal organization and sister chromatid segregation (2,6,41). Vertebrates 
have three SUMO isoforms and all three display roughly 50% identity with the 
single SUMO found in yeast (5). SUMO is conjugated to cellular substrates by an 
analogous pathway to that of ubiquitin. It has been reported that SUMOylation is 
mediated without E3 ligases in vitro (88,120), but under physiological conditions, 
SUMO E3 ligases are essential to execute SUMOylation of cellular substrates 
(8,10,11,106). There are mainly two types of SUMO E3 ligases in vertebrates, 
RanBP2 (Nup358) and Siz/PIAS. RanBP2 has no homolog in yeast and its ligase 
function is independent of either HECT or Ring finger type ubiquitin E3 ligases 
(55). Siz/PIAS, on the other hand, initially identified in budding yeast, functions 
similar to Ring finger ubiquitin ligases (11). Vertebrates have four PIAS proteins 
(PIAS1, PIAS3, PIASx, and PIASy) that share important conserved functional 
domains (70). The SAP (scaffold attachment factor-A/B, acinus and PIAS) do-
main is positioned at the N-terminus, and directly binds AT-rich regions of DNA 
(58,62,121). The SP-Ring domain is related to that of ubiquitin E3 ligase and is 
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responsible for Ubc9 recruitment (90). The SUMO-interacting motif (SIM) is situ-
ated after the SP-Ring and redirects the Ubc9~SUMO complex on substrate pro-
teins, potentially contributing to SUMO paralogue specificity (60,122). Domain 
analysis of Siz protein in vitro and in vivo suggests each domain contributes to 
SUMOylation with distinct functions. The N-terminal domain of Siz1 is involved in 
substrate recognition and the C-terminal domain in cell-cycle dependent localiza-
tion, which is critical for septin SUMOylation (123). Whether vertebrate PIAS pro-
teins are organized in a similar manner is unknown.  
Among PIAS family members, we have identified PIASy as crucial for 
SUMO2/3 modification of chromosome-associated proteins in mitosis (8). For 
example, DNA Topoisomerase IIα (TopoIIα) and Poly [ADP-ribose] polymerase I 
(PARP1) are each modified by SUMO2/3 in a PIASy-dependent manner during 
mitosis (10,71). Immunodepletion of PIASy completely abolishes mitotic chromo-
somal SUMOylation in Xenopus egg extracts (XEE) and other PIAS family pro-
teins fail to restore this defect, indicating a unique role of PIASy in mitotic chro-
mosomal SUMOylation in XEE (8). Our initial domain analysis with mutated PI-
ASy suggested that the N-terminal domain of PIASy is required for its association 
with mitotic chromosomes (8). The SUMO2/3 modification of chromosomal pro-
teins is restricted not only to the early stages of mitosis but also to the centro-
meric regions, raising the question of how PIASy regulates mitotic SUMOylation 
in a temporal and regional manner (8,10). Recent immunostaining has elucidated 
that PIASy is exclusively localized to centromeric regions and colocalizes with 
TopoIIα during mitosis, suggesting that the centromeric localization of PIASy is 
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critical for the spatiotemporal regulation of mitotic SUMOylation (Ryu et al. JCB 
In print). However, the molecular mechanism underlying this localization has re-
mained unidentified.  
Centromeres are specified regions of DNA where kinetochores are as-
sembled to capture growing microtubules from spindle poles in mitosis (124). Ki-
netochores include multiple proteins whose functions are involved in mitotic 
checkpoints directly or indirectly, and each component is absolutely required for 
the accurate progression of the cell cycle including proper chromosome segrega-
tion (16). Rod (Rough Deal) and Zw10 (Zeste White 10) are kinetochore proteins 
in higher eukaryotes (21). As a stable complex called RZZ (Rod/Zw10/Zwilch), 
Rod and Zw10 are localized to the kinetochore until anaphase commences (125). 
Rod and Zw10 are involved in mitotic checkpoint by recruiting Mad1/Mad2 and 
dynein/dynactin onto unattached kinetochores (21,25,126). Mutation of Rod, 
Zw10 or both Rod and Zw10 result in improper chromosome alignment and sister 
chromatid missegregation in Drosophila (127-129). Somatic mutations in Rod 
and Zw10 genes have been found in human colorectal cancers, implicating the 
complex in the progression of cancer (130). 
To determine how PIASy distinctively executes mitotic SUMOylation in a 
spatiotemporal manner, we have identified the mechanism of PIASy recruitment 
onto mitotic chromosomes. Using a series of purified PIASy truncations, we 
found that the N-terminal region of PIASy is vital for chromosome localization and 
for consequent mitotic SUMOylation but is dispensable for the catalytic activity in 
vitro. Additionally, we demonstrated the ability of a PIASy N-terminal peptide to 
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interact with chromosomes. Chimeric PIASy containing the N-terminal domain of 
other PIAS family proteins is defective in chromosome interaction. A PIASy N-
terminal peptide fused with mCherry is localized to the centromeric region. Im-
munofluorescence microscopy combined with biochemical analysis and mass 
spectrometry revealed that Rod and Zw10 are unique binding proteins of PIASy 
N-terminus among PIAS family proteins. Finally, we show that depletion of Rod 
proteins from XEE causes mis-localization of PIASy as well as loss of SUMO2/3 
foci on the chromosomes. Taken together, these data reveal that PIASy is re-
cruited onto the centromeric region of chromosomes through interaction of the 
PIASy N-terminus with the Rod/Zw10 kinetochore complex and this results in 
specific SUMOylation of the centromeric region.  
 
Methods 
Plasmids construction.  
The C-terminal portion, encoding amino acids 970~1060, of Rod DNA was 
cloned from Xenopus laevis tadpole cDNA (kindly provided by Drs. A. Arnaoutov 
and M. Dasso) using PCR amplification. For recombinant protein production, the 
C-terminal fragment of Rod cDNA was subcloned into pET28a and pGEX4T-1 
with BamHI/XhoI restriction enzyme sites. PIASy truncations, shown in Figure 1 
and 5 were produced by PCR and subcloned into the pET28a vector using 
EcoRI/XhoI restriction sites. N-terminal fragments of PIAS family DNAs were 
amplified from original full-length cDNA of each PIAS gene (8)  with additional 
EcoRI sites at 5’ end and HinDIII sites at 3’end, respectively, and were subcloned 
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into the pET30a vector for recombinant protein production. For N-terminal 
swapped chimeric constructs of PIASy, a DNA fragment of Xenopus laevis PIASy 
without the N-terminal domain (amino acids 142~501) was amplified by PCR 
creating HinDIII site at 5’ end and XhoI site at 3’ end, respectively, and subcloned 
into pET28a. Subsequently, the N-terminal fragments of each PIAS equivalent of 
1~141 amino acids of PIASy was ligated to the PIASy C-terminal construct. In the 
case of the C-terminal PIAS swapped chimeric constructs (y-1, y-3 and y-x in 
Figure 2), C-terminal fragment of PIAS DNAs equivalent to 410-501 amino acid 
of PIASy were amplified with additional BglII site at 5’ end and XhoI sites at 
3’end, respectively. A DNA fragment of Xenopus laevis PIASy lacking the C-
terminal domain (1- 410 amino acids) was obtained by digesting full-length PIASy 
in pET28a with EcoRI and BamHI. The C-terminal fragments of PIAS proteins 
and the PIASy (1-410) fragment were ligated into pET28a EcoRI/XhoI sites. For 
mCherry fusion of N-terminal fragments of PIASx and PIASy, PCR amplified 
mCherry cDNA (kindly provided by Dr. B. Oakley) with NotI and XhoI sites at 5’ 
and 3’ ends respectively was inserted into pET30a N-terminal PIAS constructs 
described above. cDNA of TopoIIα was subcloned into a pPIC 3.5K vector in 
which CBP-T7 Tag sequences were inserted (The CBP and ZZ TAP-tag plasmid 
was kindly provided from Dr. K. Gould). All constructs were verified by DNA se-
quencing. 
 
Recombinant protein expression and purification, and preparation of antibodies.  
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For preparation of recombinant TopoIIα proteins, the plasmids were trans-
formed into a GS115 strain of Pichia pastoris yeast and expressed according to 
the manufacturer’s instructions (Invitrogen). Protein purification with CBP was 
performed according to TAP protocol (EMBL Heidelberg) with a slight modifica-
tion of our needs. Briefly, frozen TopoIIα expressed in yeast cells were grinded 
with dried ice in a coffee mill and then mixed with lysis buffer (50mM Tris-HCl 
(pH7.5), 150mM NaCl, 2mM CaCl2, 1mM MgCl2, 0.1% Triton-X100, 5% Glycerol, 
1mMDTT and 10mM PMSF). After centrifugation at 25,000xg for 40 minutes, the 
supernatant was mixed with Calmodulin-sepharose resin (GE healthcare) for 90 
minutes at 4°C to capture CBP-tagged TopoIIα. The resin was washed with lysis 
buffer, and TopoIIα was eluted with buffer containing 10 mM EGTA. The elution 
was further purified by Mono-Q anion-exchange chromatography (GE-
healthcare).  
For preparation of the antigen for anti-Rod antibody, Both GST fused and 
His-6 tagged C- terminal fragment of Rod was expressed in BL21 (DE3) and 
His6-tagged C-terminal Rod polypeptide was purified from inclusion bodies under 
denaturing conditions (6M Urea) following the manufacture’s protocol (Clone-
thech). GST fused C-terminal Rod polypeptide was solubilized by Urea and di-
rectly conjugated to NHS-sepharose beads. All N-terminal fragments of PIAS 
family and mCherry fusion proteins were expressed in BL21 (DE3) or Rossetta2 
(DE3) (EMD Biosciences) and purified with Talone metal affinity resin 
(Clonthech) followed by ion-exchange chromatography. Preparation of E1 com-
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plex (Aos1/Uba2 heterodimer) (54), PIASy (8), Ubc9, and SUMO2 (82) were pre-
viously described.  
Polyclonal antibodies against TopoIIα C-terminus (1358-1579) were pre-
pared in rabbits by injection with recombinant His-T7 fused fragments, and affin-
ity-purified with antigens as described previously (71). Anti-PARP1, Anti-PIASy 
and anti-SUMO2/3 antibodies used this study were reported previously (8,10). 
Anti-Aurora B antibody was kindly provided from A. Arnaoutov and M. Dasso. 
Anti-Zw10 monoclonal antibody was purchased from AbCam. HRP conjugated 
anti-T7 tag antibody and S protein were purchased from EMD Biosciences.  
 
In vitro SUMOylation assay.   
The reactions were performed as previously described (10). In brief, the 
reaction contained 15 nM E1 Uba2/Aos1 heterodimer, 40 nM E2 Ubc9, 20 nM 
PIASy, 5 mM SUMO2-GG, 500 nM T7-tagged TopoIIα or PARP1 and 2.5 mM 
ATP. Reaction buffer consisted of 20 mM HEPES (pH7.8), 100 mM NaCl, 5 mM 
MgCl2, 0.05% Tween20, 5% glycerol, 1mM AEBSF and 1 mM DTT. The reac-
tions were incubated at 25°C for 1 hour and stopped by addition of one half vol-
ume of 3× SDS-PAGE sample buffer. Samples were resolved on 8-16% Tris-HCl 
gradient gels (Invitrogen) by SDS-PAGE, and analyzed by Westernblot with HRP 
conjugated anti-T7 monoclonal antibody (EMD Biosciences) or other antibodies 
as indicated.  
 
Xenopus egg extracts assays, pull-down, and immunoprecipitation. 
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Xenopus sperm chromatin and low speed cytostatic factor (CSF)-arrested 
XEE (CSF-XEE) or interphase XEE were prepared according to methods de-
scribed by Kornbluth et al. (63) with slight modification (107). In order to obtain 
mitotic chromosomes for Westernblot analysis, 5000 sperm chromatin/ml was 
incubated with freshly prepared CSF-XEE for 50 min at room temperature. 
Chromosomes were isolated as previously described (107).   
For pull-down assays from XEE, S-protein agarose beads (Novagen) or 
T7 antibody-conjugated agarose beads (Novagen) were incubated with S-tagged 
PIAS N-terminal proteins or T7-tagged PIASy truncations, respectively, as speci-
fied in figures 4 and 5 overnight at 4°C. Next day, protein-bound beads or non-
protein-bound beads were blocked with 5% gelatin for 1 hour. CSF extracts were 
diluted with two volumes of IP extract buffer (20 mM NaPi pH7.8, 18 mM b-
glycerol phosphate pH7.5, 5 mM MgCl2, 50 mM NaCl, 5% Glycerol) followed by 
centrifugation at 25,000 xg for 20min at 4°C. Supernatants were mixed with an 
equal volume of ChIP buffer (20 mM NaPi, 18 mM b-glycerol phosphate, 50 mM 
NaCl, 5 mM MgCl2, 5% Glycerol, 0.2% Tween 20, and 0.2% Triton X-100) and 
incubated with protein-bound or non-protein-bound beads for 2 hours at 25°C. 
Collected beads were washed thoroughly with ChIP buffer and PBS-T, and 
eluted in 1x SDS PAGE buffer. Samples were, then, resolved in 8-16% gradient 
gels (Invitrogen) by SDS-PAGE, and analyzed by Westernblot for the proteins 
indicated in figures 4 and 5.  
Immunoprecipitation experiments were performed in a similar way to that 
described above. Briefly, protein A Dyna beads (Invitrogen) were incubated with 
 121 
either IgG (Cont.) or antibody against PIASy C-terminus or Rod overnight at 4°C 
according to the manufacture’s manual. Antibody-bound protein A beads were 
washed with PBS-T and blocked by 5% gelatin. CSF-XEE prepared as in the 
pull-down assay was incubated with the antibody-bound beads for 2 hours at 
25°C. Collected beads were washed with ChIP buffer and PBS-T, and eluted in 
1x SDS PAGE sample buffer. Samples were resolved in 8-16% gradient gels (In-
vitrogen) by SDS-PAGE, and analyzed by Westernblot for the proteins in figure 
4. 
Immunodepletion was performed in a similar way to that previously de-
scribed (8). Briefly, antibody-bound Protein-A magnetic beads as above were 
blocked with CSF-XB buffer containing 5% BSA followed by mixing with freshly 
prepared CSF-XEE and depleted specified proteins described in Figures. For 
addback experiments, recombinant PIASy proteins or reticulocyte lysates ex-
pressing chimeric PIAS proteins were added to the PIASy-depleted CSF-XEE at 
a final concentration of 50 nM or 10% of the final reaction volume, respectively.  
 
Immunofluorescence analysis of chromosomes.  
Immunofluorescence experiments were performed as previously de-
scribed (8,10). In brief, CSF XEE was induced to undergo interphase by the addi-
tion of 0.6 mM CaCl2. 500 sperm/ml were incubated to replicate chromatins for 
~1 hour at 25°C. After checking the morphology of interphase nuclei, subse-
quently, mitosis was re-induced by the addition of one half volume of fresh CSF-
XEE. For figure 4.3, mCherry-fused PIAS N-terminal proteins were supplemented 
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immediately before inducing mitosis at a final concentration of 50 nM. After addi-
tional incubation for 40 min at 25°C, reactions were diluted three times with dilu-
tion buffer and chromosomes were fixed by addition of an equal volume of 4% p-
formaldehyde in dilution buffer. Samples were incubated for 5 min followed by 
spinning onto coverslips through a 35% glycerol cushion. After post-fixation with 
1.6% paraformaldehyde, chromosome samples were subjected to immunostain-
ing with indicated antibodies. 
For immunofluorescence study with immunodepleted XEE (Figure 4.6), anti-Rod 
antibody was crosslinked to protein A-Dyna beads with DMP (Dimethyl Pimelimi-
date⋅2HCl) according to company’s instructions (Pierce), then CSF-XEE was de-
pleted with the crosslinked anti-Rod antibody-bound bead as described above. 
Immunofluorescence experiments were performed as described above. Anti-
rabbit Alexa 568, anti-guinea pig Alexa 684, anti-mouse Alexa 488 and anti-
chicken Alexa 488 (Invitrogen) were used as secondary antibodies to visualize 
primary antibodies and DNA was visualized with Hoechst 33342 (1mg/ml). 
Specimens were observed with Nikon TE2000-U microscope equipped with Plan 
Apo 100x/1.40 objective. Images were taken with a Retiga SRV CCD camera 
(Qimageing) operated by Volocity software (Improvision). 
 
 
Results 
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The N-terminus of PIASy is dispensable for reconstituted SUMOylation as-
say in vitro but crucial for mitotic SUMOylation in Xenopus egg extract as-
says. 
    We have previously shown that PIASy is required for mitotic SUMOylation 
(8). Because mitotic SUMOylation is not fully restored by other PIAS proteins in 
PIASy-depleted XEE, it is clear that PIASy has a distinct role as an E3 ligase dur-
ing mitosis among PIAS family members (8). Domain analysis further suggested 
that this specificity is likely due to the unique ability of the N-terminal domain of 
PIASy to mediate mitotic chromosome binding (8). However, how the N-terminal 
domain facilitates the chromosome interaction of PIASy was not determined. One 
of our hypotheses was that PIASy might locate to chromosomes by the interac-
tion of its N-terminus with chromosomal substrates given that major substrates of 
PIASy, TopoIIα and PARP1, are chromosome-resident proteins (10,71). To ad-
dress this question, we sought to examine whether N-terminal deletions of PIASy 
decrease SUMOylation activity in reconstituted SUMOylation assay in vitro. We 
constructed systematic truncations that lack a series of N-terminal region of PI-
ASy (Figure 4.1A). Purified truncated proteins were applied to in vitro reactions 
for SUMO2 modification of TopoIIα or PARP1. We observed that PIASy dis-
played robust activity to SUMOylate each substrate until deleted for amino acids 
1-127 (127C) and the activity was reduced by further truncation (287C), indicat-
ing that the interaction between PIASy and each substrate was not dependent on 
the N-terminal 127 amino acids of PIASy but on the PINIT domain (Figure 4.1B). 
This result also indicates that the N-terminal 127 amino acids, including the SAP 
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domain, is dispensable for PIASy activity in vitro. Interestingly, PIASy that lacks 
the first 47 amino acids reproducibly exhibited stronger SUMOylation activity than 
full length PIASy on TopoIIα but not on PARP1 (Figure 4.1B). Further investiga-
tion is required for a clear explanation of this phenomenon.  
 
Figure 4. 1 
N-terminus of PIASy is dispensable in vitro but essential for mitotic SU-
MOylation in Xenopus egg extract assays. 
(A) Schematic diagram of PIASy truncations used in experiments in B and 
C. N-terminal deletions of PIASy are drawn to approximate scale and compared 
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to full length PIASy shown on the top. All truncation constructs and full length PI-
ASy contain a T7-tag at the N-terminus. Conserved domains among PIAS family 
are indicated as follows: SAP (scaffold attachment factor-A/B, acinus and PIAS) 
in solid black, PINIT in vertical lines, SP-Ring (Siz/PIAS-Ring) in grid, SIM 
(SUMO-interacting motif) in diamond and S/DE motif in horizontal lines. (B) In 
vitro SUMOylation assay using N-terminal truncated PIASy series. All con-
structs in A were expressed and purified as in Experimental procedure. Either 
TopoIIa or PARP1 was incubated with PIASy and Ubc9 as indicated in the pres-
ence of E1 and ATP for 1hour at 25°C and samples were analyzed by Western-
blotting with anti-T7 tag antibody, which detect recombinant TopoIIa and PARP1. 
SUMOylated and unmodified forms of proteins are specified by bracket and bar, 
respectively. The PIASy input is shown in the bottom panel. (C) PIASy immu-
nodepletion and addback experiments in Xenopus egg extracts (XEE). CSF-
XEE was immunodepleted using IgG (Mock) or anti-PIASy antibody. Purified PI-
ASy truncation proteins were added to the depleted XEE and 5,000 sperm chro-
matin/ml was incubated in the reactions at 25°C for ~1hour. The reactions with-
out (Cont.) and with dnUbc9 were also prepared for positive and negative control 
of chromosomal SUMOylation. Isolated chromosome fractions were resolved on 
SDS-PAGE gel and analyzed by Westernblot for indicated proteins. Input of PI-
ASy proteins were analyzed in the bottom panel.  
 
The function of the N-terminal domain of PIASy under physiological conditions 
was examined in a XEE cell free assay system. Cytostatic factor-arrested XEE 
(CSF-XEE) was immuno-depleted for PIASy and recombinant truncated PIASy 
proteins were used to supplement the extract in the presence of sperm chroma-
tin. Elimination of over 95% of PIASy resulted in near abolition of mitotic SUMOy-
lation, and the addition of recombinant PIASy wild type fully restored the SUMOy-
lation (Figure 4.1C, lane 1, 2, 3 and 6). Consistent with our previous studies us-
ing reticulocyte lysate (8), truncated PIASy that lacks either 47 (48C) or 127 
(127C) amino acids from the N-terminus completely failed to re-establish SU-
MOylation of mitotic chromosomal proteins (Figure 4.1C, lane 4 and 5). Only full-
length PIASy but not PIASy with N-terminal truncations was able to interact with 
chromosomes (Figure 4.1C, T7 and PIASy Westernblot), verifying that the N-
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terminus is involved in the recruitment of PIASy onto mitotic chromosomes. To-
gether, these data indicate that N-terminal domain of PIASy is not engaged in the 
interaction with its substrates and not important for SUMOylation in vitro, but fa-
cilitates chromosomal interaction and is essential for mitotic SUMOylation. 
 
Functional comparison of PIAS N-terminal domain in XEE assay.  
PIAS family proteins are categorized by several conserved domains: a 
SAP (scaffold attachment factor-A/B, acinus and PIAS) domain resides at the N-
terminus, a SP-Ring (Siz/PIAS-Ring) domain is in the middle, followed by a SIM 
(SUMO-interacting motif) (70). The SAP domains of mammalian PIAS family 
members (PIAS1, 3, xα/β, and y) are ~60% identical and ~90% similar in amino 
acid sequence. The SAP domain has been determined to bind scaffold or matrix 
attachment DNA (58,62) and, in fact, all PIAS proteins have been shown to bind 
interphase chromatin (8). Yet, only PIASy and a minor fraction of PIASx are re-
cruited to chromosomes during mitosis in XEE assays, suggesting there are 
unique features of the PIASy N-terminus that direct mitotic chromosome binding. 
To test this hypothesis, we constructed chimeras of PIAS family proteins. The 
first group of constructs was composed of SAP and SP-Ring domains from 
Xenopus laevis PIASy and the C-terminal SIM, S/DE domains from other PIAS 
proteins (y-1, y-3, y-x and y-yhs). The second group of constructs contained the 
N-terminal ~140 amino acids of either PIAS1, 3, or x protein linked with the re-
maining domains of Xenopus leavis PIASy (1-y, 3-y and x-y) (Figure 4.2A). The 
chimera constructs were transcribed and translated in rabbit recticulocyte lysates 
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(Promega) and their expression levels were verified by Westernblot with anti-T7 
tag and anti-PIASy antibodies. The PIAS3-PIASy chimeric protein (3-y) was 
barely detectable with anti-T7 tag antibody, probably due to the degradation of 
the T-7tag, but Westernblot with anti-PIASy (C-terminus) antibody indicated a 
similar level of expression of all proteins (Figure 4.2B lower panel). These 
reticulocyte lysates were supplemented into the PIASy-immunodepleted CSF-
XEE and incubated with sperm chromatin to assemble mitotic chromosomes. 
Westernblot analysis of isolated chromosomes indicated that each chimeric 
protein containing the N-terminus of PIASy was recruited to mitotic chromosomes 
(Figure 4.2C lower two panels), suggesting N-terminus of PIASy can uniquely 
facilitate chromosome binding. In contrast, constructs containing the N-terminus 
of either PIAS1, 3, or x failed to bind to chromosomes and execute TopoIIα SU-
MOylation, confirming that the N-terminus of other PIAS family members cannot 
mediate chromosome interaction. Taken together, these results indicate that the 
N-terminus of PIASy is a key element to achieve the unique role of PIASy for mi-
totic chromosomal SUMOylation by allowing interaction of PIASy to mitotic chro-
mosomes. 
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Figure 4. 2 
Comparison of function of PIAS N-terminal domains in XEE assay. 
(A) Schematic diagram of PIAS chimera proteins. The chimeric PIAS proteins 
with T7-tag at N-terminus were obtained by swapping conserved domains be-
tween PIAS family members as described in the Experimental procedures. Dia-
gram indicates the positions of swapped domain between PIAS family proteins. 
(B) Expression of the chimeric PIAS proteins in reticulocyte lysates. The 
chimera proteins constructed in A were expressed in rabbit reticulocyte lysates 
and the expression level was analyzed by Westernblot for T7 tag or anti-C-
terminus of PIASy antibody. Reticulocyte lysate containing empty vector was 
prepared for the negative control (Cont.). (C) Immunodepletion and chimeric 
PIAS addback experiments in XEEs. CSF-XEE was immunodepleted by IgG 
(Mock) or anti-PIASy antibody. Lysates prepared in B were added to the PIASy-
depleted CSF extracts, and the extracts were incubated in the presence of 5,000 
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sperm chromatin/ml for ~1hour at 25°C. Isolated chromosomes were analyzed by 
Westernblot for indicated proteins.  
 
 
The N-terminus of PIASy is sufficient for localization to the centromeric re-
gion. 
Because removal of the N terminus PIASy or replacement with the N-
terminus of other PIAS members resulted in failure to bind chromosomes, we 
sought to identify whether the N-terminal domain of PIASy simply is sufficient for 
chromosomal localization in XEE assay. To test this, fluorescent protein, 
mCherry, was fused to the N-terminal peptide of PIASx (PIASx N) or PIASy (PI-
ASy N) and expressed in bacteria. PIASx was previously shown to partially re-
store mitotic SUMOylation in the absence of PIASy but not to the same extent as 
PIASy (8). Purified proteins were added when DNA replication of sperm chroma-
tin was completed in interphase XEE, then mitosis was induced by addition of 
CSF-XEE to obtain chromosomes. The amounts of PIASx N and PIASy N added 
to the extracts were shown to be equivalent by Westernblot analysis (Fig 4.3D). 
In Figure 4.3A, Immunostaining indicated that PIASy N not only binds chromo-
somes but also accumulates at centromeric regions, resulting in colocalization 
with both SUMO2/3 and Aurora B, markers of inner-centromere, meanwhile PI-
ASx N was sparsely distributed and barely detectable. In particular, PIASy N re-
sembles the behavior of full length PIASy on chromosomes localizing at the cen-
tromeric region during mitosis (Ryu et al, JCB in print, Figure 4.3B and Figure 
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4.4D), indicating that the N-terminal ~140 amino acids of PIASy is sufficient to 
direct the localization of PIASy to the centromeric region (Figure 4.3B and C).  
 
Figure 4. 3 
N-terminal region of PIASy locates to centromere independent of its re-
maining residues. 
(A and B) Localization of mCherry-tagged N-terminal peptides of PIASx and 
PIASy. Replicated chromosomes were obtained by incubating 500 sperm nu-
clei/µl in interphase extract followed by re-entry into mitosis by CSF-XEE. N-
terminal peptides of PIASx (PIASx N) or PIASy (PIASy N) that have mCherry 
fused at the C-terminus were added before re-entry into mitosis. After re-
induction into mitosis by fresh CSF-XEE, chromosomes were spun down on cov-
erslips by centrifugation. Samples were immunostained for indicated proteins. (C) 
Centromeric localization of mCherry-fused N-terminal peptide of PIASy. 
Single sister chromatids are enlarged for the comparison of localization between 
PIASx N and PIASy N. (D) Input of PIASx N and PIASy N The amount of PIASx 
N and PIASy N input was analyzed by Westernblot with S-protein HRP (EMD Bi-
oscience), which detects the S tag at the N-terminus on both PIASx N and PIASy 
N peptides. 
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Rod and Zw10 bind to PIASy N-terminus. 
It has been shown that N-terminal domains of PIAS proteins are involved 
in protein interactions for multiple purposes (57,59). Therefore, we speculated 
that the N-terminal region of PIASy might interact with specific protein(s) for cen-
tromeric localization. In order to identify protein(s) that specifically interact with 
the N-terminus of PIASy but not with other PIAS family members, we performed 
pull-down assay with N-terminal fragments of PIAS family proteins. The 1-139 
amino acid fragment of PIASy and the equivalent residues from other PIAS pro-
teins were fused to an S-tag at the N-terminus and expressed in E. coli. Purified 
proteins were captured on S-tag affinity beads and the beads were mixed with 
XEE to isolate binding proteins. Associated proteins were separated by SDS-
PAGE and analyzed by silver staining. As shown in Figure 4.4A, several bands 
(indicated with asterisks) were reproducibly observed to associate with the PIASy 
N-terminal peptide but not with the N-termini of any other PIAS protein. Bands of 
~250 and 90 kDa were further identified as Rod and Zw10, respectively, by tan-
dem mass spectrometry. To confirm the interaction of PIASy with Rod and Zw10, 
we prepared a polyclonal antibody against Rod and obtained commercially avail-
able anti-Zw10 antibody. Westernblot analysis of samples from pull-down assays 
as shown in Figure 4.4A revealed that Rod and Zw10 specifically interact with the 
PIASy N-terminal region and not with other PIAS proteins (Figure 4.4B). We next 
investigated whether the interaction of PIASy and the identified proteins takes 
place under physiological conditions. To test this, endogenous PIASy proteins 
were immunoprecipitated from CSF-XEE with antibody against C-terminus of PI-
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ASy, and co-precipitants were analyzed with Westernblot. We observed that PI-
ASy co-precipitated with Rod, confirming that they interact in XEE bona fide. Yet, 
only a minor fraction of Rod interacts with PIASy, indicating that limited portion of 
PIASy interact to Rod or their interaction is highly transient in XEE (Figure 4.5A 
left). In a reciprocal immunoprecipation performed with an antibody against Rod, 
Rod was able to precipitate a small but detectable amount of PIASy reproducibly 
(Figure 4.5A right).  
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Figure 4. 4 
Identification of N-terminal binding proteins of PIASy. 
(A) N-terminus of PIASy has distinctive binding proteins. S-tagged N termi-
nal domains of PIAS family proteins were bound to S-agarose beads. Either S-
agarose beads (Cont.) or PIAS N-terminal protein-bound bead preparations were 
incubated in CSF XEE. Precipitated proteins together with beads were resolved 
by SDS-PAGE followed by silverstaining. Specific binding proteins for PIASy N-
terminal domain are indicated with an asterisk. S-tagged PIAS N terminal pep-
tides used as bait are indicated with bracket. (B) Confirmation of Rod and 
Zw10 binding to PIASy N-terminus. Pull-down samples as in (A) were ana-
lyzed by Westernblot for Rod and Zw10. The antibody against Rod, prepared as 
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described in Experimental procedures, or commercially available anti-Zw10 anti-
body (AbCam) were used to detect them in pull-down samples.  
 
 
Rod and Zw10 are components of a stable complex called RZZ 
(Rod/Zw10/Zwilch) (126,131). The RZZ complex is localized at kinetochores from 
pro/metaphase to metaphase in somatic cells (125). PIASy was also observed 
near centromeres in XEE assays (Figure 4.3B, Ryu et al. JCB in print). Thus, we 
sought to determine whether Rod and Zw10 interact with PIASy on mitotic chro-
mosomes using chromatin immuno-precipitation and immuno-fluorescence ap-
proaches. Chromatin immuno-precipitation of mitotic chromosomes prepared 
from XEE showed that PIASy co-precipitates Rod and Zw10 (Figure 4.5B left). 
Reciprocal analysis with an anti-Rod antibody also showed co-precipitation of 
both PIASy and Zw10 (Figure 4.5B right). Moreover, Immunofluorescence data 
indicated that Rod and Zw10 colocalize with PIASy at centromeric regions to-
gether with SUMO2/3 as expected (Figure 4.5C), supporting the idea that PIASy 
binds to the Rod/Zw10 complex for the execution of mitotic SUMOylation. It is 
also possible that PIASy directs the Rod/Zw10 complex to chromosomes. Immu-
nodepletion of PIASy in CSF-XEE, however, did not eliminate chromosomal as-
sociation of Rod/Zw10 (Figure 4.5D), arguing against PIASy-dependent chromo-
somal localization of the RZZ complex. Taken together, we conclude that Rod 
and Zw10 bind to the N-terminus of PIASy at the kinetochore, and their colocali-
zation with PIASy and immunodepletion analysis suggest that Rod/Zw10 might 
direct the centromeric localization of PIASy.  
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Figure 4. 5 
PIASy interacts with Rod/Zw10 complex on mitotic chromosomes. (A) In-
teraction of Rod and Zw10 proteins with endogenous PIASy in CSF-XEE. 
(Left) IgG or anti-PIASy antibody crosslinked protein A beads were incubated 
with CSF-XEE. Immunoprecipitated proteins were resolved in SDS-PAGE and 
analyzed by Westernblot for indicated proteins. (Right) IgG or anti-Rod antibody 
crosslinked protein A beads were incubated in CSF-XEE in the same manner. 
The precipitants were resolved by SDS-PAGE followed by Westernblot. SM 
stands for starting material. Band labeled with asterisk is a non-specific protein 
cross-reacting with anti-Rod antibody in CSF-XEE. IP: Immunoprecipitation. (B) 
Interaction of PIASy and Rod/Zw10 complex on chromosomes. Mitotic 
chromosomes prepared in CSF-XEE were subjected to Chromatin immunopre-
cipitation (ChIP) as described in Experimental procedures , and prepcitated sam-
ples were analyzed as above. (C) Localization of endogenous PIASy and 
binding proteins, Rod and Zw10. Replicated mitotic chromosome samples 
were prepared as in Figure 4.3 followed by immunostaining for the indicated pro-
teins. PIASyBPs: PIASy binding proteins. (D) Depletion of PIASy does not 
eliminate the interaction of Rod/Zw10 complex to mitotic chromosomes. 
Mock-depleted by IgG (Mock) or PIASy-depleted CSF-XEE (-PIASy) were incu-
bated in the presence of 5,000 sperm nuclei/ml for 1 hour at 25°C. Isolated 
chromosomes were resolved by SDS-PAGE and analyzed by Westernblot. The 
antibody cross-reacting band is indicated with asterisk. 
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Depletion of Rod causes mislocalization of PIASy during mitosis.  
Deletion of amino acids 1-47 of PIASy (48C) eliminates its chromosome 
binding (Figure 4.1C), suggesting that a protein interacting with the first 47 resi-
dues is critical for chromosome localization. Thus, we sought to further character-
ize where Rod and Zw10 interact within the N-terminal 140 amino acid region of 
PIASy, which we used as bait in pull-down assay (Figure 4.4). To this end, serial 
truncation constructs of PIASy that contain T7 tag at the N-terminus were pre-
pared (Figure 4.6A). Purified truncation proteins were bound to anti-T7 tag anti-
body-conjugated beads followed by incubation in CSF-XEE. Westernblot analysis 
of pull-downed proteins by the beads indicated that Rod and Zw10 interact with 
full length of PIASy similar to data shown in Figure 4.4. Strikingly, those interac-
tions were no longer observed with PIASy that 1-47 amino acids were deleted 
(48C) as well as with further truncations (Figure 4.6B). Consistent with pull-down 
result in Figure 4.4, PIASy (N325) with a C-terminal deletion retained the interac-
tion with Rod and Zw10, confirming that the Rod/Zw10 complex binds to the N-
terminus, but not the C-terminus of PIASy. This result reveals that the interaction 
of the Rod/Zw10 complex with PIASy is restricted to 1-47 amino acids of the N-
terminus, the region critical for chromosome localization of PIASy (Figure 4.1C). 
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Figure 4. 6 
Rod/Zw10 complex interacts with the first 47 reside of PIASy protein.  
(A) Schematic diagram of PIASy and its truncations used in B. PIASy and its 
truncations contain T7-tag at the N-terminus. (B) Further identification of 
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Rod/Zw10-interacting area on PIASy protein. Purified T7-tagged PIASy trun-
cation proteins as well as full length (WT) were bound to T7 antibody-conjugated 
agarose beads. Protein bound beads or beads alone (Cont.) were incubated with 
CSF-XEE. The precipitated proteins together with the T7-antibody beads were 
resolved by SDS-PAGE and analyzed by Westernblot for the indicated proteins 
or Coomassie staining. SM: starting material. 
 
It has been shown that PIASy-dependent SUMOylation is confined to the 
centromeric region of chromosomes in mitosis (8,10). Given that the Rod/Zw10 
complex is localized at the kinetochore, we hypothesized that the Rod/Zw10 
complex is required for PIASy to localize to the centromeric region. To address 
this question, we immuno-depleted endogenous Rod and examined the localiza-
tion of PIASy and of SUMOylation. The efficiency of Rod depletion was ~80% 
(Figure 4.7C) and a Rod signal was detected by immunofluorescence on some 
chromosomes prepared from Rod-depleted XEE (-Rod), albeit its signal was 
much weaker than the one in Mock-depleted samples (-IgG). Nonetheless, it was 
evident that the centromeric localization of Rod was completely linked to that of 
PIASy: chromosomes containing Rod showed the centromeric localization of PI-
ASy without exception while ones without Rod had mis-localized PIASy on the 
chromosomes (Figure 4.7A, compare chromosomes indicated with arrows and 
squares). Rod-deficient chromosomes never showed clear PIASy foci, rather 
they showed dispersed and weak signals of PIASy. Chromosome samples were 
also stained with another anti-PIASy antibody for further confirmation. We consis-
tently observed mislocalized PIASy on the Rod-depleted chromosomes, but 
rarely on Mock-depleted chromosomes (Figure 4.7B). It was notable that Rod-
deficient chromosomes showed loss of intensive SUMO2/3 foci presumed to lo-
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cate near centromeres, following mislocalization of PIASy (Figure 4.7A, B and 
4.8). All together, our data indicate that the Rod/Zw10 complex is required for the 
centromeric localization of PIASy and spatial regulation of SUMO2/3 modification 
near the centromere. 
 
Figure 4. 7 
Rod/Zw10 complex is required for localization of PIASy on centromeric re-
gion as well as SUMO2/3 during mitosis.  
(A and B) Immunodepletion of Rod causes mis-localization of PIASy on mi-
totic chromosomes. (A) CSF-XEE was immunodepleted for Rod and released 
into interphase by the addition of CaCl2. Sperm chromatin was incubated with the 
interphase extracts, and sister chromatids were obtained from the replicated 
chromatin by the addition of Rod-depleted CSF-XEE (-Rod). CSF-XEE was also 
mock-depleted using non specific IgG and processed as above (-IgG). Isolated 
chromosome samples were subjected to immunostaining for proteins as indi-
cated. Affinity purified anti-PIASy chicken IgY and anti-SUMO2/3 Guinea Pig IgG 
were used to visualize PIASy and SUMO2/3, respectively. (B) Samples in A were 
immunostained with affinity purified anti-PIASy antibody obtained from Rabbit. 
The chromosome lacking Rod protein is shown in squares. The chromosome that 
still contains Rod in Rod-depleted samples is indicated with arrows. The centro-
mere-specific localization of both PIASy and SUMO modification was compro-
mised if Rod was completely eliminated. (C) Confirmation of Rod depletion. 
CSF-XEE before and after immunodepletion with anti-IgG or Rod antibody were 
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analyzed for the indicated proteins. Asterisk shows background signals from an-
tibody cross-reacting in CSF extracts. (D) Model for molecular mechanism of 
PIASy-dependent centromeric SUMOylation during mitosis. PIASy interacts 
with the Rod/Zw10 complex at the kinetochore through its N-terminal region (des-
ignated as N). Consequently, Ubc9-SUMO2/3 adduct is recruited onto centro-
meric regions via binding to PIASy and facilitates SUMO2/3 modification of sub-
strates such as TopoIIa and PARP1 in a spatially regulated manner 
 
 
 
 
Figure 4. 8 
Loss of Rod/Zw10 complex causes mis-localization of SUMO2/3 on mitotic 
chromosomes. CSF-XEE was immunodepleted for Rod and released into inter-
phase by the addition of CaCl2. Sperm chromatin was incubated in the inter-
phase extracts for ~ 1 hour, and sister chromatids were obtained from the repli-
cated chromatin by the addition of Rod-depleted CSF-XEE (-Rod). CSF-XEE was 
also mock-depleted using non-specific IgG and processed as above (-IgG). Iso-
lated chromosome samples were subjected to immunostaining for proteins as 
indicated. Affinity purified anti-Rod rabbit antibody and anti-SUMO2/3 Guinea Pig 
antibody were used to visualize Rod and SUMO2/3, respectively. DNA was visu-
alized with Hoechst33342. 
 
 
 
DISCUSSION 
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Biological significance of the PIASy N-terminal domain  
We have thoroughly characterized PIASy, an essential SUMO E3 ligase of 
mitotic substrates, using both systematic in vitro domain analysis and Xenopus 
egg extract cell free assays. It was previously demonstrated that the PIASy N-
terminus, mostly composed of a SAP domain, plays a key role in chromosome 
interaction (8). Recent studies have shown that Siz1, a Siz/PIAS SUMO E3 li-
gase in budding yeast, interacts with substrates via its N-terminal domain 
(90,123), suggesting that the N-terminal domain of Siz/PIAS is responsible for 
substrate binding. Given that major substrates of PIASy are chromosome-
resident proteins in mitosis, we hypothesized that the N-terminus of PIASy 
achieves chromosome binding through the interaction with its substrates. In vitro 
analysis using purified N-terminal PIASy truncations revealed that the first 127 
amino acids of PIASy are dispensable for SUMOylation in vitro, with further dele-
tion [including PINIT domain (59,90)] starting to affect SUMOylation (Figure 
4.1B). This finding suggests that N-terminus anterior to the PINIT domain is not 
involved in substrate binding. Conversely, XEE assays have shown that the first 
47 amino acids of PIASy, including the SAP domain, is absolutely required for 
mitotic SUMOylation (Figure 4.1C), strongly suggesting that the PIASy N-
terminus binds specific molecule(s) to mediate chromosomal localization, and 
that the interaction between PIASy and these partners is critical for mitotic SU-
MOylation.  
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A number of studies have described a discrepancy between in vivo and in 
vitro substrate specificity of Siz/PIAS proteins of SUMO E3 ligases (12,123,132). 
It has been suggested that subcellular localization of SUMO E3 ligases is crucial 
for substrate specificity in vivo (12,123,132). Our XEE assays have shown that 
chimera PIASy proteins containing the N-terminus of PIAS1, 3, or x fail to interact 
with chromosomes and fail to facilitate mitotic SUMOylation (Figure 4.2). We 
have also shown that the N-terminus of PIASy is sufficient to direct localization to 
the centromeric region (Figure 4.3), arguing that PIAS proteins display substrate 
specificity by means of subcellular localization. The SAP domain was character-
ized as a putative A/T rich DNA binding domain, yet proteins such as p53, Msx1, 
and Oct-4 interact with specific PIAS proteins through their SAP domain 
(62,133,134). We have identified that the N-terminus of PIASy containing the 
SAP domain interacts with kinetochore-associated proteins, Rod and Zw10 (Fig-
ure 4.4 and 4.6), raising the possibility that the SAP domain contributes to protein 
interactions for regulating subcellular localization of PIAS proteins. It will be of 
interest to investigate whether the SAP domain-mediated localization is a com-
mon mechanism to regulate the localization of other PIAS family proteins in cells. 
This information will provide insight into the in vivo substrate specificity of mam-
malian PIAS family proteins.  
 
Molecular mechanism of PIASy recruitment to the kinetochore 
PIASy-dependent SUMOylation becomes detectable in prometaphase, 
peaks in metaphase and disappears with the onset of anaphase (71). This mitotic 
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phase-specific SUMOylation is further restricted to the inner centromere (8). Here 
we show that PIASy binds to kinetochore proteins, Rod and Zw10; components 
of the RZZ complex, through its N-terminus (Figure 4.4, 4.5 and 4.6) and that 
elimination of Rod compromises PIASy localization to kinetochores (Figure 4.7). 
These results suggest that the Rod/Zw10 complex has a critical role in the cen-
tromeric recruitment of PIASy and, thus, in the SUMOylation of chromosomal 
substrates near the centromere. Previous studies in Drosophila embryos re-
vealed that GFP-Rod enters the nucleus by the time that nuclear envelope 
breaks down, accumulates on kinetochores, and disperses as sister chromatids 
are separated (125). This aspect of Rod and Zw10 distribution during mitosis 
highly resembles PIASy distribution, leading to an explanation for how PIASy 
executes centromeric SUMOylation during mitosis. We propose that PIASy ac-
cumulates on kinetochores by docking with Rod/Zw10 complex that is concen-
trated on kinetochores when the nuclear envelope disassemble and then PIASy 
facilitates SUMO2/3 modification of its substrates (TopoIIα and PARP1) near the 
centromere (Figure 4.7D). As Rod and Zw10 are shed from kinetochores, PIASy 
falls off and SUMO modification decreases. One puzzling observation is that PI-
ASy is mislocalized but does not fail to interact with chromosomes deficient in 
Rod/Zw10 complex. This does not fit with the observation that PIASy lacking first 
47 residues failed to interact with chromosomes (Figure 4.1B), implying that there 
might be another protein(s) delivering PIASy close to chromosomes. Further 
analysis of PIASy movement dynamics in mitosis may elucidate this question. 
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The RZZ complex delivers dynein/dynactin onto unattached kinetochores 
(135). The complex also functions in activating spindle assembly checkpoint sig-
naling by bringing two checkpoint components, Mad1 and Mad2 (22,25). In Dro-
sophila and C. elegans, the phenotypes of mutation in Rod, Zw10, or both cause 
as premature chromosome segregation with anaphase bridges (128,131). Com-
ponents of the SUMO pathway are clearly connected to mitosis. Mutations in 
SUMO (smt3, pmt3), Aos1, and Ubc9 show defects in mitotic progression in bud-
ding and fission yeast (50,105,136,137). Defects in SUMO modification also 
show chromosomal missegregation in XEE (8,71). Given that the Rod/Zw10 
complex is required for proper centromeric localization of PIASy and SUMO 
modification (Figure 4.7 and 4.8), it is reasonable to consider that the RZZ com-
plex could regulate two completely different pathways: metaphase checkpoint 
and centromeric SUMOylation. If so, the abnormal chromosome segregation 
shown in Rod/Zw10 mutants might be the dual outcome from defects in both the 
mitotic checkpoint and the SUMO pathway.  
In summary, we have demonstrated the molecular mechanism of PIASy-
dependent SUMOylation in mitosis by showing that PIASy interacts with the 
Rod/Zw10 complex, a kinetochore component, through its SAP domain in the N-
terminus. Our results suggest that the SAP domain of PIAS family proteins could 
show binding specificity that plays a critical role in determination of substrate 
specificity in vivo. Together, our studies reveal the likely molecular mechanism of 
PIASy-dependent spatiotemporal regulation of SUMO modification and a novel 
role of the RZZ kinetochore complex on chromosomal SUMOylation.  
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CHAPTER 5 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
           Since the discovery of SUMOylation in 1996, mounting information has 
revealed that SUMO conjugation regulates many aspects of cellular function at 
various stages of the cell cycle (41,42,64).  During interphase, numerous tran-
scription factors are targeted for SUMOylation and, once modified, change their 
binding patterns, leading to alterations in transcription levels (42).  During mito-
sis, various centromeric proteins are modified by SUMO, and the combination of 
these modifications ultimately contributes to proper cell division (41).  One of 
these centromeric resident proteins, DNA topoisomerase IIα (TopoIIα) was first 
determined to be a SUMO substrate in yeast (102).  Yeast TopoIIα mutants inca-
pable of SUMO modification displayed abnormal chromosome segregation, sug-
gesting that SUMO modification is involved in proper mitotic progression (102).  
 We utilized Xenopus egg extracts (XEE) and an in vitro reconstitution as-
say to elucidate how SUMOylation regulates TopoIIα during mitosis (71). The 
advantages of our approach are twofold.  First, mitosis-dependent SUMOylation 
can be completely isolated from interphase-dependent SUMOylation in XEE.  
Secondly, the spatiotemporal limits of studying SUMOylation in XEE (namely, 
that SUMOylation occurs at the centromeric region during mitosis) can be over-
come by using an in vitro reconstitution assay. By isolating chromosome fractions 
 150 
from XEE, we also identified PARP1, (an enzyme involved in the repair of single 
strand DNA breaks), as a novel mitosis-specific substrate for SUMO2/3 conjuga-
tion (10).  We demonstrated that Lys 482 on PARP1 is a major site for SUMO2/3 
conjugation, in a PIASy-dependent manner (10). Finally, the SUMO E3 ligase 
PIASy was extensively examined to determine the molecular dynamics of mitotic 
SUMOylation (118).   
 In the following paragraphs, the effects of SUMOylation on mitotic pro-
gression, and how PIASy contributes to cell cycle-specific SUMO conjugation, 
will be discussed.  The section will conclude with a discussion of future directions 
for this work. 
 
Functional analysis of mitotic SUMOylation 
PARP1 SUMOylation in mitosis 
 PARP1 is an enzyme that assembles a chain of ADP-ribose moieties on 
PARP1 itself and on its substrates, using NAD+ as an ADP-ribose source (35). 
PARP1-mediated PARylation plays a role in DNA damage repair during inter-
phase, and the interaction of PARP1 with BRCA1/2 has lead to the identification 
of PARP1 as a potential anti-cancer target (138).  In addition, it has been shown 
that upon detection of DNA damage, PARP1-mediated PARylation prevents pro-
gression of mitosis by inhibiting the activity of aurora kinase B, a molecule impli-
cated in spindle checkpoint control, thus underlining the importance of mitotic 
PARP1 activity in cell cycle progression (38).  
 We identified PARP1 as a target for SUMO2/3 conjugation in a cell cycle-
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specific manner (10).  SUMO conjugation of PARP1 first appears when the cell 
cycle is near metaphase, and disappears, with the onset of anaphase.  We have 
also shown that PARP1-mediated PARylation is negatively affected by SUMO2/3 
conjugation.  Elimination of SUMOylation increases PARylation in mitosis.  Be-
cause of the inability to restore immunodepleted PARP1 by adding back recom-
binant PARP1 proteins in XEE, in future studies, siRNA and mutant constructs of 
nonSUMOylatable PARP1 will be utilized in cell lines in order to fully understand 
the role of PARP1 SUMOylation in mitosis.  To this end, the identification of all of 
the SUMOylation sites of PARP1 will be necessary.  Also, identifying the poten-
tial substrates and binding proteins of PARP1 during mitosis, and determining 
how SUMOylation affects these will add to our understanding of this regulatory 
mechanism. 
 
TopoIIα SUMOylation in mitosis 
 DNA topoisomerase IIα (TopoIIα) is responsible for proper chromosome 
segregation during mitosis (8,93). This is likely because of the catalytic activity 
(catenation and decatenation) of TopoIIα being able to resolve DNA topology. 
Catenation and decatenation of DNA are identical biochemical reactions, and the 
ionic strength determines either reaction in certain circumstance (139,140). Our 
research revealed that SUMO conjugation regulates the catalytic activity of 
TopoIIα in vitro (141).  Using a reconstitution assay, we were able to generate 
SUMO-conjugated forms of TopoIIα.  After this modification process, SUMOy-
lated TopoIIα and non-SUMOylated control were applied in a decatenation assay 
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in which TopoIIα activity can be assessed.  Our results indicated that TopoIIα 
decatenation activity is strongly inhibited by SUMO2/3 conjugation.  Tandem 
mass spectrometric analysis in XEE and in vitro confirmed that Lys 660 is an 
endogenously SUMOylated site on TopoIIα.  Using a mutated molecule that re-
places Lys 660 with Arg, we showed that the K660R mutant does not allow SU-
MOylation-dependent inhibition of TopoIIα activity, leading to the conclusion that 
SUMOylation negatively regulated TopoIIα activity through Lys 660 conjugation.  
A remaining concern is that, because Lys 660 is located within the catalytic do-
main of TopoIIα, the K660R mutant protein has ~20 times less activity than wild-
type, although the DNA binding capacity of the mutant is not affected. Thus, it is 
not clear whether abolition of SUMOylation-dependant inhibition of TopoIIα activ-
ity is affected by the lower catalytic activity of the mutant.  The remaining SU-
MOylation sites of TopoIIα will have to be identified in order to answer this ques-
tion.  
 In summary, cell cycle-specific SUMO2/3 conjugation during mitosis ap-
pears to negatively affect the intrinsic activity of its target proteins, based on the 
results with PARP1 and TopoIIα.  It is likely that the temporal inhibition of 
TopoIIα activity directs the accurate progression of the mitotic phases:  inhibition 
of TopoIIα by SUMOylation prevents both recatenation and premature chromo-
some segregation that may occur when the catalytic activity of TopoIIα persists.  
Further experiments using the K660R or equivalent mutants in the in vivo system 
are necessary in order to understand the function of TopoIIα SUMOylation under 
physiological conditions.  
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Molecular mechanism of centromeric SUMOylation 
 SUMO conjugation of mitotic substrates has been observed mainly within 
the centromeric region of chromosomes.  It was previously reported that PIASy is 
required for centromeric SUMOylation (8).  However, the details of this molecular 
modification and its effect on mitosis are unknown.    
 The PIAS family of SUMO E3 ligases is comprised of PIAS1, PIAS3, PI-
ASxα, PIASxβ, and PIASy (57).  All have the same basic structural elements, 
with an N-terminal, conserved SAP motif, an internal SP-RING domain, and 
variations in their C-terminal sequences (57).  However, only PIASy is able to 
bind to chromosomes during mitosis (8).  Because of the unique mitotic SUMOy-
lation capacity of PIASy, we analyzed the subdomains of the PIASy protein.  Us-
ing recombinant truncated PIASy proteins, we determined that the sequence re-
sponsible for chromosome binding was the N-terminal region, including the SAP 
domain (118).  This was surprising, given the small size (~130 amino acids) and 
sequence similarity to other PIAS proteins.  We found that the 130 amino acid 
polypeptide was sufficient not only to bind to chromosomes, but also to locate to 
the centromeric area (118).  This localization is consistent with that of full length 
PIASy protein (which is restricted to the centromeric region) and with the fact that 
SUMO modification occurs in the vicinity of the centromere on chromosomes 
(71).  
       We subsequently analyzed the binding partners of the PIASy N-terminal do-
main.  Mass spectrometry indicated that both Rod (Rough deal) and Zw10 (Zeste 
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white 10) are binding partners of PIASy.  Rod forms a complex with Zw10 and 
Zwilch in vertebrates (21).  The complex then recruits the checkpoint proteins 
Mad1 and Mad2 to the kinetochore and thus is required for spindle checkpoint 
activation (22,126,127). We demonstrated that Rod and Zw10 bind only to the 
PIASy protein, and not to other PIAS family members. Immunodepletion of PIASy 
does not affect Rod/Zw10 localization, but immunodepletion of Rod/Zw10 eradi-
cates the centromeric localization of PIASy, indicating that the Rod/Zw10 com-
plex recruits PIASy to the centromeric region.  We also found that binding of 
Rod/Zw10 occurs within the first 49 amino acids of PIASy, in the region com-
posed of the SAP domain.  The DNA binding function of SAP has been previ-
ously described (58), however, this result suggests the novel concept that PIAS 
proteins utilize their SAP domain for proper cellular localization as well. 
 
Combining the pieces to develop a picture of mitotic SUMOylation 
 Based on our results, we can trace the process of SUMOylation that oc-
curs during mitosis as follows:  Once the nuclear envelope breaks down, the 
Rod/Zw10 complex gains access to the kinetochore on the chromosomes.  PI-
ASy is then able to locate to the centromeric region by binding to Rod/Zw10. PI-
ASy recruits the activated SUMO2/3-Ubc9 complex and facilitates the SUMOyla-
tion of target proteins near the centromere.  TopoIIα, one of these SUMO target 
proteins, is immediately made inert by SUMOylation, thereby, blocking any fur-
ther entanglement or disentanglement of centromeric DNA.  SUMO conjugation 
of another target, PARP1, halts PARylation.  When mitotic checkpoints are com-
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pleted, the Rod/Zw10 complex begins to fall off the kinetochores, thus weakening 
the interaction between PIASy and the centromeric region.  As PIASy disap-
pears, SUMO modification is reversed by nearby SUMO proteases, leading to 
the reactivation of TopoIIα (Figure 5.1). 
 
 
Figure 5. 1. 
A molecular model for the PIASy-dependent mechanism of mitotic SUMOylation.  Once the nu-
clear envelope breaks down, the Rod/Zw10 complex localizes to the centromeric region. Subse-
quently, PIASy recognizes the Rod/Zw10 complex through its N-terminus and is recruited to the 
centromeric region. Centromere-resident SUMO target proteins such as TopoIIα and PARP1 are 
modified by SUMO2/3 in a PIASy-dependent manner.  The catalytic activity of TopoIIα is regu-
lated by SUMO modification during mitosis. 
 
 
In summary, we endeavored to examine the field of mitotic SUMOylation in order 
to address the following questions:  
1)  What is the role of SUMO conjugation of TopoIIα during mitosis?   
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2)  Are there other targets for SUMOylation in mitosis?   
3) How does centromeric SUMOylation take place in such a well-defined, spatio-
temporal manner?  
In answer to these questions, we found that:  
1)  SUMO2/3 conjugation inhibits the intrinsic activity of TopoIIα through modifi-
cation of Lys 660 in vitro.  
2)  PARP1 is a novel SUMO2/3 substrate during mitosis in Xenopus egg ex-
tracts.  Lys 482 is a major SUMOylation site in PARP1 during mitosis.  
3)  PIASy mediates centromeric SUMOylation through its N-terminal binding to 
chromosomes.  PIASy exclusively localizes at the centromeric region during mi-
tosis, and this centromeric localization is executed through binding of Rod/Zw10 
complex proteins.  
 
 In future work, the identification of the remaining SUMOylation sites of 
TopoIIα will clarify the role of Lys 660 SUMOylation in the regulation of TopoIIα 
activity.  Identification of the SUMOylation sites on TopoIIα will further elucidate 
other potential roles for SUMOylation that, at present, remain unidentified.   
 It is also of great interest to identify why PARylation increases when 
PARP1 is not SUMOylated.   
 Lastly, PIASy was shown to be able to interact with chromosomes without 
the presence of the Rod/Zw10 complex, suggesting that there are other ways to 
recruit PIASy to chromosomes.  Therefore, identifying this route is another future 
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goal, in order to completely understand the molecular mechanism of mitotic SU-
MOylation.    
 
Reference 
 1.  Melchior, F. (2000) Annu Rev Cell Dev Biol 16, 591‐626 2.  Hay, R. T. (2005) Mol Cell 18, 1‐12 3.  Fraser, A. G., Kamath, R. S., Zipperlen, P., Martinez‐Campos, M., Sohrmann, M., and Ahringer, J. (2000) Nature 408, 325‐330 4.  Saitoh, H., and Hinchey, J. (2000) J Biol Chem 275, 6252‐6258 5.  Johnson, E. S. (2004) Annu Rev Biochem 73, 355‐382 6.  Bossis, G., and Melchior, F. (2006) Cell Div 1, 13 7.  Sampson, D. A., Wang, M., and Matunis, M. J. (2001) J Biol Chem 276, 21664‐21669 8.  Azuma,  Y.,  Arnaoutov,  A.,  Anan,  T.,  and Dasso, M.  (2005) Embo  J 24,  2172‐2182 9.  Ryu, H., and Azuma, Y. (2010) J Biol Chem 285, 32576‐32585 10.  Ryu,  H.,  Al‐Ani,  G.,  Deckert,  K.,  Kirkpatrick,  D.,  Gygi,  S.  P.,  Dasso,  M.,  and Azuma, Y. (2010) J Biol Chem 285, 14415‐14423 11.  Johnson, E. S., and Gupta, A. A. (2001) Cell 106, 735‐744 12.  Takahashi, Y., Toh, E. A., and Kikuchi, Y. (2003) J Biochem 133, 415‐422 13.  Melchior, F., Schergaut, M., and Pichler, A. (2003) Trends Biochem Sci 28, 612‐618 14.  Mukhopadhyay, D., and Dasso, M. (2007) Trends Biochem Sci 32, 286‐295 15.  Salaun, P., Rannou, Y., and Prigent, C. (2008) Adv Exp Med Biol 617, 41‐56 16.  Santaguida, S., and Musacchio, A. (2009) Embo J 28, 2511‐2531 17.  Nasmyth, K. (2002) Science 297, 559‐565 18.  Lew, D. J., and Burke, D. J. (2003) Annu Rev Genet 37, 251‐282 19.  Eckert, C. A., Gravdahl, D. J., and Megee, P. C. (2007) Genes Dev 21, 278‐291 20.  Cheeseman, I. M., and Desai, A. (2008) Nat Rev Mol Cell Biol 9, 33‐46 21.  Karess, R. (2005) Trends Cell Biol 15, 386‐392 22.  Kops, G. J., Kim, Y., Weaver, B. A., Mao, Y., McLeod, I., Yates, J. R., 3rd, Tagaya, M., and Cleveland, D. W. (2005) J Cell Biol 169, 49‐60 23.  Ge, S., Skaar, J. R., and Pagano, M. (2009) Cell Cycle 8, 167‐171 24.  Robbins, J. A., and Cross, F. R. (2010) Cell Div 5, 23 25.  Buffin, E., Lefebvre, C., Huang,  J., Gagou, M. E., and Karess, R. E.  (2005) Curr 
Biol 15, 856‐861 26.  Chan, G. K.,  Jablonski, S. A., Starr, D. A., Goldberg, M. L., and Yen, T. J. (2000) 
Nat Cell Biol 2, 944‐947 27.  Shamu, C. E., and Murray, A. W. (1992) J Cell Biol 117, 921‐934 
 158 
28.  Takahashi,  Y.,  Yong‐Gonzalez,  V.,  Kikuchi,  Y.,  and  Strunnikov,  A.  (2006) 
Genetics 172, 783‐794 29.  Bloom, K., and Joglekar, A. (2010) Nature 463, 446‐456 30.  Uemura, T., Ohkura, H., Adachi, Y., Morino, K., Shiozaki, K., and Yanagida, M. (1987) Cell 50, 917‐925 31.  Downes, C. S., Mullinger, A. M., and Johnson, R. T. (1991) Proc Natl Acad Sci U 
S A 88, 8895‐8899 32.  Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. (1996) Nature 379, 225‐232 33.  Andersen,  C.  L.,  Wandall,  A.,  Kjeldsen,  E.,  Mielke,  C.,  and  Koch,  J.  (2002) 
Chromosome Res 10, 305‐312 34.  Schreiber, V., Dantzer, F., Ame, J. C., and de Murcia, G. (2006) Nat Rev Mol Cell 
Biol 7, 517‐528 35.  Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., and Poirier, G. G. (2010) 
Nat Rev Cancer 10, 293‐301 36.  Ahel, D., Horejsi, Z., Wiechens, N., Polo, S. E., Garcia‐Wilson, E., Ahel, I., Flynn, H.,  Skehel, M., West,  S.  C.,  Jackson,  S. P., Owen‐Hughes, T.,  and Boulton,  S.  J. (2009) Science  37.  Masson, M., Niedergang,  C.,  Schreiber, V., Muller,  S., Menissier‐de Murcia,  J., and de Murcia, G. (1998) Mol Cell Biol 18, 3563‐3571 38.  Monaco, L., Kolthur‐Seetharam, U., Loury, R., Murcia, J. M., de Murcia, G., and Sassone‐Corsi, P. (2005) Proc Natl Acad Sci U S A 102, 14244‐14248 39.  Seufert, W., Futcher, B., and Jentsch, S. (1995) Nature 373, 78‐81 40.  Nacerddine,  K.,  Lehembre,  F.,  Bhaumik,  M.,  Artus,  J.,  Cohen‐Tannoudji,  M., Babinet, C., Pandolfi, P. P., and Dejean, A. (2005) Dev Cell 9, 769‐779 41.  Dasso, M. (2008) Cell Div 3, 5 42.  Gill, G. (2005) Curr Opin Genet Dev 15, 536‐541 43.  Mahajan, R., Delphin, C., Guan, T., Gerace, L., and Melchior, F. (1997) Cell 88, 97‐107 44.  Stade,  K.,  Vogel,  F.,  Schwienhorst,  I.,  Meusser,  B.,  Volkwein,  C.,  Nentwig,  B., Dohmen, R. J., and Sommer, T. (2002) J Biol Chem 277, 49554‐49561 45.  Long, J., Wang, G., He, D., and Liu, F. (2004) Biochem J 379, 23‐29 46.  Poukka, H., Karvonen, U., Janne, O. A., and Palvimo, J. J. (2000) Proc Natl Acad 
Sci U S A 97, 14145‐14150 47.  Lin, D. Y., Fang, H. I., Ma, A. H., Huang, Y. S., Pu, Y. S., Jenster, G., Kung, H. J., and Shih, H. M. (2004) Mol Cell Biol 24, 10529‐10541 48.  Chang,  C.  C.,  Lin, D.  Y.,  Fang, H.  I.,  Chen, R. H.,  and Shih, H. M.  (2005)  J Biol 
Chem 280, 10164‐10173 49.  Dieckhoff,  P.,  Bolte,  M.,  Sancak,  Y.,  Braus,  G.  H.,  and  Irniger,  S.  (2004) Mol 
Microbiol 51, 1375‐1387 50.  Tanaka, K., Nishide, J., Okazaki, K., Kato, H., Niwa, O., Nakagawa, T., Matsuda, H., Kawamukai, M., and Murakami, Y. (1999) Mol Cell Biol 19, 8660‐8672 51.  Denison, C., Rudner, A. D., Gerber, S. A., Bakalarski, C. E., Moazed, D., and Gygi, S. P. (2005) Mol Cell Proteomics 4, 246‐254 52.  Stead, K., Aguilar, C., Hartman, T., Drexel, M., Meluh, P., and Guacci, V. (2003) J 
Cell Biol 163, 729‐741 
 159 
53.  Sachdev, S., Bruhn, L.,  Sieber, H., Pichler, A., Melchior, F.,  and Grosschedl, R. (2001) Genes Dev 15, 3088‐3103 54.  Pichler, A., Gast, A., Seeler,  J. S., Dejean, A., and Melchior, F. (2002) Cell 108, 109‐120 55.  Pichler, A., Knipscheer, P., Saitoh, H., Sixma, T. K., and Melchior, F. (2004) Nat 
Struct Mol Biol 11, 984‐991 56.  Hochstrasser, M. (2001) Cell 107, 5‐8 57.  Rytinki, M. M., Kaikkonen, S., Pehkonen, P., Jaaskelainen, T., and Palvimo, J. J. (2009) Cell Mol Life Sci 66, 3029‐3041 58.  Aravind, L., and Koonin, E. V. (2000) Trends Biochem Sci 25, 112‐114 59.  Duval, D., Duval, G., Kedinger, C., Poch, O., and Boeuf, H. (2003) FEBS Lett 554, 111‐118 60.  Hecker,  C. M.,  Rabiller, M., Haglund, K.,  Bayer,  P.,  and Dikic,  I.  (2006)  J  Biol 
Chem 281, 16117‐16127 61.  Munarriz,  E.,  Barcaroli,  D.,  Stephanou,  A.,  Townsend,  P.  A.,  Maisse,  C., Terrinoni, A., Neale, M. H., Martin, S. J., Latchman, D. S., Knight, R. A., Melino, G., and De Laurenzi, V. (2004) Mol Cell Biol 24, 10593‐10610 62.  Okubo,  S., Hara,  F.,  Tsuchida,  Y.,  Shimotakahara,  S.,  Suzuki,  S., Hatanaka, H., Yokoyama, S., Tanaka, H., Yasuda, H., and Shindo, H. (2004) J Biol Chem 279, 31455‐31461 63.  Kornbluth, S., Yang, J., and Powers, M. (2001) Analysis of the Cell Cycle Using Xenopus Egg Extracts. in Current Protocols in Cell Biology (M. Yamada, K. ed.), John Wiley & Sons, Inc., New York, NY. pp 11.11.11‐11.11.13 64.  Geiss‐Friedlander,  R.,  and Melchior,  F.  (2007) Nat Rev Mol  Cell  Biol 8,  947‐956 65.  Seeler,  J.  S.,  Bischof,  O.,  Nacerddine,  K.,  and  Dejean,  A.  (2007)  Curr  Top 
Microbiol Immunol 313, 49‐71 66.  Heun, P. (2007) Curr Opin Cell Biol 19, 350‐355 67.  Hannich,  J.  T.,  Lewis,  A.,  Kroetz,  M.  B.,  Li,  S.  J.,  Heide,  H.,  Emili,  A.,  and Hochstrasser, M. (2005) J Biol Chem 280, 4102‐4110 68.  Panse, V. G., Hardeland, U., Werner, T., Kuster, B., and Hurt, E.  (2004)  J Biol 
Chem 279, 41346‐41351 69.  Wohlschlegel, J. A., Johnson, E. S., Reed, S. I., and Yates, J. R., 3rd. (2004) J Biol 
Chem 279, 45662‐45668 70.  Palvimo, J. J. (2007) Biochem Soc Trans 35, 1405‐1408 71.  Azuma, Y., Arnaoutov, A., and Dasso, M. (2003) J Cell Biol 163, 477‐487 72.  Wong, K. A., Kim, R., Christofk, H., Gao, J., Lawson, G., and Wu, H. (2004) Mol 
Cell Biol 24, 5577‐5586 73.  Diaz‐Martinez,  L.  A.,  Gimenez‐Abian,  J.  F.,  Azuma,  Y.,  Guacci,  V.,  Gimenez‐Martin, G., Lanier, L. M., and Clarke, D. J. (2006) PLoS One 1, e53 74.  D'Amours, D., Desnoyers, S., D'Silva, I., and Poirier, G. G. (1999) Biochem J 342 
( Pt 2), 249‐268 75.  Kim, M. Y., Zhang, T., and Kraus, W. L. (2005) Genes Dev 19, 1951‐1967 76.  Ame, J. C., Spenlehauer, C., and de Murcia, G. (2004) Bioessays 26, 882‐893 77.  Chang, P., Jacobson, M. K., and Mitchison, T. J. (2004) Nature 432, 645‐649 78.  Chang, P., Coughlin, M., and Mitchison, T. J. (2005) Nat Cell Biol 7, 1133‐1139 
 160 
79.  Saxena,  A., Wong,  L.  H.,  Kalitsis,  P.,  Earle,  E.,  Shaffer,  L.  G.,  and  Choo,  K.  H. (2002) Hum Mol Genet 11, 2319‐2329 80.  Saxena, A.,  Saffery, R., Wong, L. H., Kalitsis, P.,  and Choo, K. H.  (2002)  J Biol 
Chem 277, 26921‐26926 81.  Caiafa, P., Guastafierro, T., and Zampieri, M. (2009) Faseb J 23, 672‐678 82.  Azuma, Y., Tan, S. H., Cavenagh, M. M., Ainsztein, A. M., Saitoh, H., and Dasso, M. (2001) Faseb J 15, 1825‐1827 83.  Kane, S., Sano, H., Liu, S. C., Asara, J. M., Lane, W. S., Garner, C. C., and Lienhard, G. E. (2002) J Biol Chem 277, 22115‐22118 84.  Messner, S., Schuermann, D., Altmeyer, M., Kassner,  I., Schmidt, D., Schar, P., Muller, S., and Hottiger, M. O. (2009) Faseb J  85.  Glover, J. N., Williams, R. S., and Lee, M. S. (2004) Trends Biochem Sci 29, 579‐585 86.  Earle,  E.,  Saxena,  A., MacDonald,  A.,  Hudson, D.  F.,  Shaffer,  L.  G.,  Saffery,  R., Cancilla, M. R., Cutts, S. M., Howman, E., and Choo, K. H. (2000) Hum Mol Genet 
9, 187‐194 87.  Quenet, D., El Ramy, R., Schreiber, V., and Dantzer, F. (2009) Int J Biochem Cell 
Biol 41, 60‐65 88.  Bernier‐Villamor, V., Sampson, D. A., Matunis, M. J., and Lima, C. D. (2002) Cell 
108, 345‐356 89.  Masson,  M.,  Menissier‐de  Murcia,  J.,  Mattei,  M.  G.,  de  Murcia,  G.,  and Niedergang, C. P. (1997) Gene 190, 287‐296 90.  Yunus, A. A., and Lima, C. D. (2009) Mol Cell 35, 669‐682 91.  Yanagida, M. (2009) Nat Rev Mol Cell Biol 10, 489‐496 92.  Diaz‐Martinez,  L.  A.,  Gimenez‐Abian,  J.  F.,  and  Clarke,  D.  J.  (2008)  J  Cell  Sci 
121, 2107‐2114 93.  Porter, A. C., and Farr, C. J. (2004) Chromosome Res 12, 569‐583 94.  Lee, M. T., and Bachant, J. (2009) DNA Repair (Amst) 8, 557‐568 95.  Ishida, R., Sato, M., Narita, T., Utsumi, K. R., Nishimoto, T., Morita, T., Nagata, H., and Andoh, T. (1994) J Cell Biol 126, 1341‐1351 96.  Gorbsky, G. J. (1994) Cancer Res 54, 1042‐1048 97.  Tavormina,  P.  A.,  Come,  M.  G.,  Hudson,  J.  R.,  Mo,  Y.  Y.,  Beck,  W.  T.,  and Gorbsky, G. J. (2002) J Cell Biol 158, 23‐29 98.  Wang,  L. H., Mayer,  B.,  Stemmann, O.,  and Nigg,  E.  A.  (2010)  J  Cell  Sci 123, 806‐813 99.  Schoeffler, A. J., and Berger, J. M. (2008) Q Rev Biophys 41, 41‐101 100.  Isaacs, R. J., Davies, S. L., Sandri, M. I., Redwood, C., Wells, N. J., and Hickson, I. D. (1998) Biochim Biophys Acta 1400, 121‐137 101.  Ishida, R., Takashima, R., Koujin, T., Shibata, M., Nozaki, N., Seto, M., Mori, H., Haraguchi, T., and Hiraoka, Y. (2001) Cell Struct Funct 26, 215‐226. 102.  Bachant,  J., Alcasabas, A., Blat, Y., Kleckner, N.,  and Elledge,  S.  J.  (2002) Mol 
Cell 9, 1169‐1182 103.  Watts, F. Z. (2007) Chromosoma 116, 15‐20 104.  Hari, K. L., Cook, K. R., and Karpen, G. H. (2001) Genes Dev 15, 1334‐1348 105.  Biggins,  S.,  Bhalla,  N.,  Chang,  A.,  Smith,  D.  L.,  and  Murray,  A.  W.  (2001) 
Genetics 159, 453‐470 
 161 
106.  Dawlaty, M. M., Malureanu, L., Jeganathan, K. B., Kao, E., Sustmann, C., Tahk, S., Shuai, K., Grosschedl, R., and van Deursen, J. M. (2008) Cell 133, 103‐115 107.  Azuma, Y. (2009) Methods Mol Biol 582, 221‐231 108.  Arnaoutov, A., and Dasso, M. (2003) Dev Cell 5, 99‐111 109.  Walker,  J.  V.,  Nitiss,  K.  C.,  Jensen,  L.  H.,  Mayne,  C.,  Hu,  T.,  Jensen,  P.  B., Sehested, M., Hsieh, T., and Nitiss, J. L. (2004) J Biol Chem 279, 25947‐25954 110.  Chang, C.  J., Goulding, S., Earnshaw, W. C., and Carmena, M. (2003)  J Cell Sci 
116, 4715‐4726 111.  Xue, Y., Zhou, F., Fu, C., Xu, Y., and Yao, X. (2006) Nucleic Acids Res 34, W254‐257 112.  Schoeffler, A. J., and Berger, J. M. (2005) Biochem Soc Trans 33, 1465‐1470 113.  Dong, K. C., and Berger, J. M. (2007) Nature 450, 1201‐1205 114.  Roca, J., Berger, J. M., Harrison, S. C., and Wang, J. C. (1996) Proc Natl Acad Sci 
U S A 93, 4057‐4062 115.  Agostinho, M., Santos, V., Ferreira, F., Costa, R., Cardoso, J., Pinheiro, I., Rino, J., Jaffray, E., Hay, R. T., and Ferreira, J. (2008) Cancer Res 68, 2409‐2418 116.  Baldwin, E. L.,  and Osheroff, N.  (2005) Curr Med Chem Anticancer Agents 5, 363‐372 117.  Joseph, J., Tan, S. H., Karpova, T. S., McNally, J. G., and Dasso, M. (2002) J Cell 
Biol 156, 595‐602 118.  Ryu, H., and Azuma, Y. (2010) J Biol Chem  119.  Wang,  L.  H.,  Schwarzbraun,  T.,  Speicher,  M.  R.,  and  Nigg,  E.  A.  (2008) 
Chromosoma 117, 123‐135 120.  Yunus, A. A., and Lima, C. D. (2006) Nat Struct Mol Biol 13, 491‐499 121.  Suzuki,  R.,  Shindo,  H.,  Tase,  A.,  Kikuchi,  Y.,  Shimizu,  M.,  and  Yamazaki,  T. (2009) Proteins 75, 336‐347 122.  Sekiyama,  N.,  Ikegami,  T.,  Yamane,  T.,  Ikeguchi,  M.,  Uchimura,  Y.,  Baba,  D., Ariyoshi, M., Tochio, H., Saitoh, H., and Shirakawa, M. (2008) J Biol Chem 283, 35966‐35975 123.  Reindle, A., Belichenko, I., Bylebyl, G. R., Chen, X. L., Gandhi, N., and Johnson, E. S. (2006) J Cell Sci 119, 4749‐4757 124.  Torras‐Llort, M., Moreno‐Moreno, O., and Azorin, F. (2009) Embo J 28, 2337‐2348 125.  Basto, R., Scaerou, F., Mische, S., Wojcik, E., Lefebvre, C., Gomes, R., Hays, T., and Karess, R. (2004) Curr Biol 14, 56‐61 126.  Williams, B. C., Li, Z., Liu, S., Williams, E. V., Leung, G., Yen, T. J., and Goldberg, M. L. (2003) Mol Biol Cell 14, 1379‐1391 127.  Lu, Y., Wang, Z., Ge, L., Chen, N., and Liu, H. (2009) Cell Struct Funct 34, 31‐45 128.  Scaerou,  F.,  Aguilera,  I.,  Saunders,  R.,  Kane,  N.,  Blottiere,  L.,  and  Karess,  R. (1999) J Cell Sci 112 ( Pt 21), 3757‐3768 129.  Basto, R., Gomes, R., and Karess, R. E. (2000) Nat Cell Biol 2, 939‐943 130.  Wang,  Z.,  Cummins,  J. M.,  Shen,  D.,  Cahill,  D.  P.,  Jallepalli,  P.  V., Wang,  T.  L., Parsons, D. W., Traverso, G., Awad, M., Silliman, N., Ptak, J., Szabo, S., Willson, J. K., Markowitz, S. D., Goldberg, M. L., Karess, R., Kinzler, K. W., Vogelstein, B., Velculescu, V. E., and Lengauer, C. (2004) Cancer Res 64, 2998‐3001 
 162 
131.  Scaerou, F., Starr, D. A., Piano, F., Papoulas, O., Karess, R. E., and Goldberg, M. L. (2001) J Cell Sci 114, 3103‐3114 132.  Kotaja, N., Karvonen, U., Janne, O. A., and Palvimo, J. J. (2002) Mol Cell Biol 22, 5222‐5234 133.  Tolkunova, E., Malashicheva, A., Parfenov, V. N., Sustmann, C., Grosschedl, R., and Tomilin, A. (2007) J Mol Biol 374, 1200‐1212 134.  Lee, H., Quinn, J. C., Prasanth, K. V., Swiss, V. A., Economides, K. D., Camacho, M. M., Spector, D. L., and Abate‐Shen, C. (2006) Genes Dev 20, 784‐794 135.  Starr, D. A., Williams, B. C., Hays, T. S., and Goldberg, M. L. (1998)  J Cell Biol 
142, 763‐774 136.  al‐Khodairy, F., Enoch, T., Hagan, I. M., and Carr, A. M. (1995) J Cell Sci 108 ( 
Pt 2), 475‐486 137.  Shayeghi, M., Doe, C. L., Tavassoli, M., and Watts, F. Z. (1997) Nucleic Acids Res 
25, 1162‐1169 138.  Bryant, H. E.,  Schultz, N., Thomas, H. D.,  Parker, K. M.,  Flower, D.,  Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., and Helleday, T. (2005) Nature 434, 913‐917 139.  Baldi, M.  I.,  Benedetti,  P., Mattoccia,  E.,  and Tocchini‐Valentini,  G.  P.  (1980) 
Cell 20, 461‐467 140.  Mertz, J. E., and Miller, T. J. (1983) Mol Cell Biol 3, 126‐131 141.  Ryu, H., Furuta, M., Kirkpatrick, D., Gygi, S. P., and Azuma, Y. (2010) J Cell Biol 
191, 783‐794   
 
 
 
